Effects of single nucleotide polymorphisms in leptin and pro-opiomelanocortin on peripheral eucocyte counts in beef cattle by Asiamah, Patience Agyarko
EFFECTS OF SINGLE NUCLEOTIDE POLYMORPHISMS IN LEPTIN AND PRO-
OPIOMELANOCORTIN ON PERIPHERAL LEUCOCYTE COUNTS IN BEEF 
CATTLE 
 
 
 
 
 
 
A Thesis Submitted to the College of 
Graduate Studies and Research 
in Partial Fulfillment of the Requirements 
for the Degree of Master of Science 
in the Department of Animal and Poultry Science 
University of Saskatchewan 
Saskatoon 
 
 
 
 
 
 
By 
 
 
Patience Agyarko Asiamah 
 
 
 
 
 
 
© Copyright Patience Agyarko Asiamah, August 2005. All rights reserved. 
PERMISSION TO USE 
 
 
          In presenting this thesis in partial fulfillment of the requirements for a Postgraduate 
degree from the University of Saskatchewan, I agree that the libraries of this University 
may make it freely available for inspection.  I further agree that permission for copying of 
this thesis in any manner, in whole or in part, for scholarly purposes may be granted by 
the professor or professors who supervised my thesis work, or in their absence, by the 
Head of the Department or Dean of the College in which my thesis work was done.  It is 
understood that any copying or publication or use of this thesis or parts thereof for 
financial gain shall not be allowed without my written permission.  It is also understood 
that due recognition shall be given to me and the University of Saskatchewan in any 
scholarly use which may be made of any material in my thesis. 
 
          Requests for permission to copy or make use of material in this thesis in whole or 
in part should be addressed to: 
 
 
 Head of the Department of Animal and Poultry Science 
 University of Saskatchewan 
 Saskatoon, Saskatchewan S7N 5A8 
 
 
 
 
 
 
 
 i
ABSTRACT 
 
 
          Single nucleotide polymorphisms (SNP) in leptin (LEP) and pro-opiomelanocortin 
(POMC) have been associated with beef carcass quality and yield respectively.  Both 
hormones also play a role in immune performance.  Since both of these genes are 
pleiotrophic, it was important to determine whether selection based on these SNPs would 
negatively affect immune cell numbers.  A SNP in each of these hormones was assessed 
for effects on immune cell counts and antibody titres in twenty-seven beef cattle herds (n 
= 556).  A commercial rabies vaccine was administered to these animals.  Prior to being 
vaccinated, the types of lymphocytes evaluated included B cells, gamma delta cells, 
regular and activated CD4 and CD8 cells and numbers of lymphocytes as well as baseline 
serum antibody titres.  On day 21, antibody titres were measured and a booster vaccine 
was administered.  Finally on day 42, antibody titres and lymphocyte types were again 
counted.  Several cell types were significantly associated with the LEP genotype 
however, no consistent pattern of correlation was observed between LEP genotype (TT, 
CT or CC) and peripheral blood lymphocyte populations. The number of different 
lymphocytes significantly associated with LEP genotype increased from two on day 0 to 
four on day 42.  Animals with CT and CC genotypes had significantly higher increased 
rabies antibody titres in the first 21 days after vaccination than those with TT genotypes.  
The POMC SNP also did not show a clear pattern of association between lymphocyte 
subtypes and genotype.  There was no difference in response to the rabies vaccination 
associated with the POMC genotype.  Our results suggested that selection at either of the 
SNPs examined in this research would not detrimentally impact immune function in beef 
cattle. 
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1.0. GENERAL INTRODUCTION 
 
          Prior to the outbreak of the mad cow disease in May 2003, the beef cattle industry 
contributed about $13 billion to the economy of Canada (Bird 2001).  With this 
substantial contribution to the nation’s economy, it is critical that proper steps are taken 
to ensure a healthy cattle production system in order to maximize profit.  The optimum 
functioning of the immune system in cattle is imperative since it plays a major role in 
maintaining the animals’ performance and growth efficiencies. 
          Without the effective protective measures employed by the immune system, it is 
possible that a majority of living things would perish due to the presence of numerous 
harmful organisms.  These harmful organisms are able to access the body through 
inhalation, contacting the epithelial surfaces and ingestion among others.  The immune 
system is an assembly of immunoglobulins and lymphocytes, which are cross-linked to 
eradicate foreign materials that enter the body. 
          This project was designed to investigate the roles played by leptin and pro-
opiomelancortin (POMC) in the immune system of beef cattle.  Leptin is the protein 
product of the obese gene secreted predominantly by the adipose tissue, which was found 
to be associated with appetite and energy metabolism (Zhang et al. 1994; Houseknecht et 
al. 1998; Lamas et al. 2004).  A single nucleotide polymorphism (SNP) in this gene was 
found to be associated with carcass quality and milk yield in beef and dairy cattle  
 
 
 
 1
respectively (Buchanan et al. 2002; 2003).  As a consequence, selection for the beneficial 
allele or the allele with economic advantage is occurring.  Recent publications have 
indicated leptin’s ability to influence immune performance (Lord et al., 1998; Faggioni et 
al. 1999; Lamas et al. 2004; Matarese et al. 2005). 
          Similarly, POMC, a hormone produced in the anterior pituitary, also plays a role in 
appetite regulation (Mori, 2001; Pritchard et al.2002) and a SNP has also been identified 
(Thue and Buchanan 2003) which is associated with yield in beef cattle (Buchanan et al. 
2005).  POMC has also been found to modulate some aspects of the immune system 
(Mechanick et al.1992; Adachi et al. 1999). 
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2.0. LITERATURE REVIEW 
 
 
2.1. Background to the immune function 
 
 
          The resistance to diseases, especially infectious diseases, is referred to as 
immunity.  The immune system is the basic mechanism by which the body recognizes, 
fights and eliminates foreign materials that enters it.  The result is the survival of the 
body against the pathogenic organisms to which it is exposed.  Without effective 
protective measures, diseases caused by pathogenic organisms or toxins produced by 
microorganisms would have denied a huge number of living things their survival and 
performance.  The immune system is a collection of cells, tissues and organs that function 
together to mediate resistance to infections.  Physiologically, the immune system 
prevents infections as well as fights existing infections (Goldsby et al. 2000). 
          The efficiency of the immune system is dependent on a number of factors 
including genetic, nutritional, degree of exposure to immunogenic factors and whether 
there has been a previous encounter with a particular immunogenic factor.  Multiple 
systems have to be present to be effective against the different pathogens and the 
different levels at which they can attack the body.  For instance, some invaders will act 
on body surfaces, fluids or in cells.  Effective elimination of invaders requires multiple 
defense mechanisms that can act both on the surface and within cells to destroy 
organisms (Tizard 2000).  Hence the protection of the body depends on a complex system 
of overlapping and interconnected defense mechanisms that act together to destroy 
almost all invaders (Tizard 2000). 
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          Basically, there are two main types of immune response.  These are innate and 
adaptive immune responses.  Innate immune response is a general non-specific type of 
response, which acts as the first line of combating diseases (Abbas and Lichtman 2001).  
Innate immunity is always present in healthy individuals to block the entry of microbes 
and to rapidly eliminate microbes that are able to enter host tissues.  It is also known as 
native or natural immunity.  Adaptive immunity is a specific immune response that is 
stimulated by microbes.  It is also known as specific or acquired immunity.  Adaptive 
immunity usually is a follow up to innate immunity should the mechanisms employed by 
innate immunity fail to eradicate the disease or infection. 
 
 
2.1.1 Innate immunity 
 
          This is the first line of defense of the immune system.  It is the non-specific 
component of immunity hence its mechanisms are not peculiar to a particular pathogen 
(Goldsby et al. 2000).  It is mediated by epithelial barriers, phagocytes, natural killer cells 
and several plasma proteins including proteins of the complement system.  Innate 
immunity usually occurs within the first few hours (about 0-12 hours) after antigens enter 
the body by evading the anatomical and physiological barriers (Abbas and Lichtman 
2001). 
          Anatomical barriers include the skin and mucous membranes.  The skin acts as a 
keratinized physical barrier.  Sebatious glands, found in the skin secret sebum.  Sebum 
contains lactate and fatty acids.  These acids maintain the skin pH between 3 and 5 thus 
preventing the survival of many organisms (Abbas and Lichtman 2001).  The mucous 
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secretions such as saliva and tears wash away pathogens.  Mucous secretions may also 
contain lysosome, a membrane-bound acidic organelle that contains proteolytic enzymes 
that degrade proteins derived mainly from the extra cellular environment.  The 
continuous epithelia that line the skin, gastrointestinal and respiratory tracts contain intra-
epithelial lymphocytes as well as peptide antibiotics, which prevent or fight the entry of 
microbes. 
          Physiological barriers include body temperature; maintained at 37oC for humans, 
39oC for cattle and 41oC for poultry, skin pH (3-5); and stomach pH (1.5-3.5).  Survival 
of microorganisms at such temperatures and pH levels is limited (Abbas and Lichtman 
2001).  For example, the body temperature of chickens prevents the growth of the anthrax 
bacteria (Goldsby et al. 2000).  Interferons secreted by virally infected cells induce a non-
viral state in neighboring cells.  During infection, the secretion of acute phase protein 
such as serum amyloid A and C-reactive protein is increased. 
          Although physical barriers are very useful, they are sometimes unable to clear the 
invaders due to the persistence of the invaders (Tizard 2000).  The mechanism employed 
by innate immunity is that it recognizes and responds to microbes but does not react 
against non-microbial substances (Abbas and Lichtman 2001).  For example, phagocytes 
have receptors for bacterial lipopolysaccharides (LPS) also called endotoxins, terminal 
mannose residues on glycoproteins, double stranded RNA and unmethylated CpG 
nucleotides all of which are components of bacteria and/or viruses. 
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          Collectively, these structures shared by classes of microbes are referred to as 
molecular patterns (Abbas and Lichtman 2001).  Receptors for innate immunity have the 
ability to recognize molecular patterns.  Host cells that have been damaged by microbes 
may also trigger an innate immune response.  Innate immunity attacks microbial 
substances needed for the survival of the microbes.  For this reason, mutation of the 
microbes does not allow the microbes to elude innate immunity.  Microbial recognition 
receptors of innate immunity are encoded in the germ line.  This results in limited 
diversity in the receptors of innate immunity.  Receptors of innate immunity are non 
clonal, and are identical on all cells of the same lineage. 
          This is different from adaptive immune receptors, which are clonal.  This means 
that in adaptive immunity, clones of lymphocytes with distinct specificities express 
different receptors.  Innate immune response is capable of discriminating between self 
and non-self antigens.  Host cells are not recognized or they may express molecules that 
prevent innate immune reactions. 
          The principal cells of innate immunity are the phagocytes (neutrophils and 
monocytes/ macrophages) and the Natural Killer (NK) cells.  Neutrophils, the most 
abundant blood phagocytes number about 4,000 to 10,000 per cubic millimeter of blood 
(Abbas and Lichtman 2001).  Production of neutrophils in the bone marrow increases in 
response to infection to about 20,000 per cubic millimeter of blood.  The role of the 
neutrophils is to ingest microbes in blood and tissues.  Monocytes differentiate into 
macrophages in extravascular tissues.  Macrophages secrete the cytokines interleukin - 1 
(IL-1) and tumor necrosis factor (TNF), which act on the endothelium to release two 
adhesion molecules, E-selectin and P-selectin to bind carbohydrates expressed by 
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neutrophils and monocytes.  Together with integrins, selectin mediates the rolling of cells 
on the endothelium.  The endothelial cells produce cytokines known as chemokines, 
which bind to endothelial membrane proteins and stimulate the motility of leucocytes. 
          As a result, the leucocytes begin to migrate through the vessel wall and along the 
chemokine concentration gradient to the site of infection.  NK cells produce interferon 
gamma (INF-γ), which is a cytokine that activates macrophages to secret more of IL-1 
and TNF-α.  INF-γ plays important physiological roles to back up innate and adaptive 
immune responses.  In its absence, cellular responsiveness in humans and experimental 
animals significantly predisposes the host to microbial infection, a result that affirms the 
physiologic importance of this cytokine in preventing infectious diseases (Ikeda et al. 
2002).  NK cells are responsible for killing infected host cells.  The production of IL-1 
and TNF-α as a result of the activation of macrophages by INF-γ allows the cycle to go 
on to eliminate infected host cells. 
 
 
2.1.2 Adaptive immunity 
 
          Adaptive or specific immunity is the type of host defense that is stimulated by 
microbes that invade tissues (Abbas and Lichtman 2001).  This component of immunity 
is able to recognize and selectively eliminate specific foreign microorganisms and 
molecules (Goldsby et al. 2000).  Cells employed by adaptive immune response are 
mainly the B and T lymphocytes produced in the bone marrow by hematopoiesis (the 
development of mature blood cells in the bone marrow and fetal liver).  B-lymphocytes 
mature in the bone marrow.  T lymphocytes migrate to the thymus where they undergo  
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T-cell education and maturation.  This further development of T cells in the thymus is to 
enable the T cells to recognize and eliminate foreign antigens whilst being able to tolerate 
or ignore self-antigens (Abbas and Lichtman 2001). 
          T lymphocytes are differentiated into T cytotoxic or T cytolytic (TC) and T helper 
cells (TH).  T cytotoxic cells express the membrane glycoprotein called CD8+ that kill 
cells harboring intracellular microbes by lysis of these cells.  T helper cells express 
membrane glycoprotein called CD4+ cells.  TH cells activate B cells to produce antibodies 
and help phagocytes to destroy ingested microbes hence the name T helper cells.  There 
are two types of T helper cells namely TH1 and TH2 cells.  TH1 cells produce cytokines 
such as IL-2, which is required for T cell proliferation, and interferon gamma (INF-γ), 
which is responsible for stimulating phagocytes that function in the elimination of 
intracellular microbes. 
               TH2 cells on the other hand mediate anti-helminthic and hypersensitive 
responses by producing IL-4 and IL-5, which stimulate immunoglobulin E (Ig E) and 
eosinophils.  In addition to these cytokines that function in antihelminthic responses, TH2 
cells also produce IL-6 and IL-13.  IL-6 stimulates the synthesis of acute phase proteins 
by hepatocytes (Abbas and Lichtman 2001). 
            TH1 and TH2 cytokines work differently and TH2 down regulates TH1 responses.  
The effectiveness of cell-mediated immune response against microbes is dependent on 
the balance between the productions of TH1and TH2 cells in response to that microbe 
(Abbas and Lichtman 2001).  Eradication of an infectious microbe depends on the  
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relative activation of TH1 and TH2.  The possibility of using TH1-type cytokine genes in 
the treatment of cancer has been explored by Roth and Cristiano (1997) whereas TH2 
cytokines have been used effectively to inhibit autoimmune diseases (Prud’homme 2000) 
          Adaptive immunity displays a high degree of specificity as well as the remarkable 
property of memory.  Specificity is a means by which specific lymphocytes are produced 
to combat specific antigens.  This is important because different lymphocytes bearing 
antigen receptors are required for different antigens.  When activated, T cytotoxic cells 
differentiate into effector cells that can destroy infected cells.  The rearrangement to 
produce specific lymphocyte receptors enable all kinds of antigens to be combated except 
the host’s own potentially antigenic substance known as self antigens.  After the 
elimination of the microbes some of the lymphocytes remain in the body.  These are 
referred to as memory cells.  The purpose of the memory cells is to give a rapid and 
higher response to the same antigen for which it was produced upon a second encounter.  
Adaptive immune response employs lymphocytes and their products, mainly cytokines 
and antibodies, to eliminate the antigen.  Adaptive immune responses against antigens 
occur within five or six days after the initial exposure to that antigen. 
          There are two types of adaptive immunity namely humoral and cell-mediated 
immune responses.  Humoral adaptive response occurs in body fluids in circulation.  It is 
mediated by antibody production by the B-lymphocytes and combats microbes that enter 
blood circulation.  It is primarily directed against exogenous/extra cellular invaders.  
Antibodies can recognize a wide variety of macromolecules including proteins, 
polysaccharides, lipids and nucleic acids.  Antigen recognition by antibodies begins with 
the coming together (cross-linking) of two or more of receptor molecules.  The receptors 
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are noncovalently attached to protein molecules namely immunoglobulin α (Igα) and 
immunoglobulin β (Igβ) to form the B cell receptor complex (BCR).  Igα and Igβ 
transmit signals of antigen recognition to evoke immune response. 
          Cell-mediated immune response occurs in the cells by the action of Tc (CD8+) 
lymphocytes.  Cell mediated immune response is responsible for combating microbes that 
are found in the body cells.  Invaders cause cellular abnormalities. Cell mediated 
immunity is primarily directed against endogenous/intracellular invaders.  Specialized 
cytotoxic cells destroy the abnormal cells.  Whereas B cells recognize a wide variety of 
molecules without the need for an intermediary host presentation, most T cells can 
recognize only peptides.  Specialized host presentation molecules must present the 
peptides recognized by T cells. 
          The specialized host presenting molecules are known as major histocompatibility 
(MHC) molecules.  This property of T cells is called MHC restriction.  There are two 
types of MHCs namely MHC class 1 and MHC class 2.  MHC Class 1 molecules are 
expressed on all nucleated cells, but MHC class 2 molecules are expressed mainly on 
professional antigen presenting cells (APCs) such as dendritic cells, macrophages and B-
lymphocytes.  MHC Class 1 molecules have a peptide-binding cleft that can 
accommodate 8 to 11 amino acids (Abbas and Lichtman 2001).  MHC Class 2 molecules 
have a peptide-binding cleft that is large enough to accommodate peptides of 10 to 30 
residues (Abbas and Lichtman 2001). 
          The variability in the MHC receptors is determined by the genetic constitution and 
differs greatly among individuals except for identical twins.  Due to such great diversity 
in MHC molecules, susceptibility to diseases varies among individuals (Abbas and 
 10
Lichtman 2001).  MHC also regulates the choice of mating partners in individuals (Tizard 
2000).  For instance, under controlled conditions, mice would mate with MHC-
incompatible partners.  The results of such matings are MHC-heterozygous progeny, 
which are better able to resist diseases (Tizard 2000). 
          The T cell receptor (TCR) recognizes antigens by means of α and β chains attached 
to the receptor.  After the TCR recognizes antigens, it requires a transmission of 
biochemical signals to the interior of the cell in order to trigger an immune response.  
Two molecules, namely, CD3 and ζ that are non-covalently attached to the TCR, perform 
this signaling role. The TCR, CD3 and ζ together form the TCR complex. 
          When a microbe breaches the epithelium and enters the sub-epithelial tissue, 
macrophages respond by producing cytokines.  Two of these cytokines, interleukin 1 (IL-
1) and tumor necrosis factor (TNF-α) stimulate the endothelium to produce two adhesion 
molecules namely E-selectin and P-selectin.  Selectin binds loosely to circulating 
neutrophils and monocytes.  Flowing blood disrupts this bond, but the bond reforms.  
This results in the rolling of the leucocytes on the endothelial surface aided by integrins-
another set of adhesion molecules expressed by activated leucocytes, which causes a firm 
adhesion of leucocytes to endothelial surfaces.  Another cytokine, named chemokine is 
produced both by the tissue macrophage that encountered the microbe and by endothelial 
cells responding to macrophage-derived IL-1 and TNF- α.  Chemokines stimulate the 
leucocytes to move through the vessel wall along the chemokine concentration gradient 
to the site of infection. 
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          The sequence of selectin-mediated rolling, integrin-mediated firm adhesion, and 
chemokine mediated motility leads to the migration of blood leucocytes to an 
extravascular site of infection within minutes after the infection.  Leucocytes accumulate 
at the site of infection.  Vascular dilation occurs and there is the increased permeability of 
the vessels.  These three processes are together referred to as inflammation.  
Inflammation involves the accumulation and activation of leucocytes and plasma proteins 
at the site of infection, toxin exposure or cell injury. 
 
 
2.1.3. Cytokines 
 
          Cytokines are secreted proteins (in the range of 5-20kD) that function as mediators 
of immune response (Abbas and Lichtman 2001).  They act as hormones of the immune 
system that facilitate immune response.  They either act in an autocrine (acting on cells 
that they are produced from) or paracrine (acting on cells other than the ones that they are 
produced from) manner.  Structurally defined cytokines are referred to as interleukins.  In 
innate immunity cytokines are produced by macrophages and NK cells and by mainly T 
lymphocytes in adaptive immunity. 
          Cytokines produced by macrophages include TNF-α, IL-1 and IL-12.  TNF-α 
stimulates the recruitment of neutrophils and kills microbes.  It stimulates vascular 
endothelial cells to secret chemokines.  Excessive production of TNF-α in severe 
infections results in septic shock.  IL-1 mediates host inflammatory response in innate 
immunity, induces endothelial cell adhesion molecules and stimulates chemokine 
production by endothelial cells and macrophages (Abbas and Lichtman 2001). 
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IL-12 is a key inducer of cell-mediated immune responses to intracellular microbes.  IL-
12 activates NK cells, enhances cytotoxic activity of NK cells and cytotoxic T 
lymphocytes and promotes the proliferation of TH1cells.  Macrophages therefore function 
in both innate and adaptive immunity (Abbas and Lichtman 2001). 
          NK cells are a proportion of peripheral blood lymphocytes, which are neither T nor 
B cells but belong to a distinct population of cytotoxic lymphocytes (Tizard 2000). 
NK cells produce INF-γ to activate phagocytes in both innate and adaptive immune 
responses.  NK cells form about 10 percent of the total lymphocyte count in blood and 
peripheral lymphoid organs (Abbas and Lichtman 2001).  They respond to microbes by 
killing infected cells and by producing INF-γ, which is a macrophage activating cytokine.  
Macrophages in turn produce IL-12, which functions to activate NK cells.  NK cells do 
not express immunoglobulins or T-cell receptors but have abundant cytoplasmic granules 
and are likely to have receptors for structures found on host cells infected with viruses 
and on phagocytes harboring viruses and intracellular bacteria.  NK cells also express 
receptors for the fragment crystalline (Fc) portions of some immunoglobulin G antibodies 
and use these receptors to bind to cells coated with antibodies.  Fc is that portion of an 
immunoglobulin molecule that binds to a cell when the antibodies are occupied or the 
antibody is aggregated. 
          When NK are activated, they exhibit two major responses.  They kill infected host 
cells by discharging of their proteins contained within their cytoplasmic granules towards 
the infected cells.  Secondly, INF-γ synthesized by activated NK cells activates  
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macrophages to become more effective at killing phagocytosed microbes.  T lymphocytes 
produce the cytokines INF-γ, TNF-α and chemokines that act as assessory molecules in 
the mechanism by which T cells eradicate external agents that enter the body. 
 
 
2.1.4 Immune cell types relevant to this project 
 
          Other immune cell types that have been mentioned in this project include CD4, 
CD5, CD8, CD21, CD25, CD26, and CD45. 
 
CD refers to cluster of differentiation and are cell surface molecules expressed on various 
cell types in the immune system (Abbas and Lichtman 2001). 
 
CD4: -Originally called T4 is a specific receptor for MHC class 2 molecules (Abbas and 
Lichtman 2001).  CD4 plays a key role in the recognition of processed antigen by helper 
T cells.  It is a 59-kDa glycoprotein found on helper T cells, thymocytes and monocytes.  
It is also a cell-binding receptor for HIV. 
 
CD5: -A 67-kDa molecule whose ligand is CD72.  It is found on a subset of B cells and on 
all T cells.  If CD5 is blocked, T cells will no longer respond to antigens.  Its expression 
on B cells varies among species.  Thus it is found on all rabbit B cells and on a 
subpopulation of B cells in most species including mice and humans, but it is not found 
on B cells in rats or dogs. 
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CD8: -It is a 32kDa dimeric glycoprotein that used to be called T8.  It is a specific 
receptor for MHC class 1 found on cytotoxic T cells.  CD8 plays a key role in the 
recognition of endogenous antigens by these cells. 
 
CD21: A complement receptor also called CR2.  It is a glycoprotein of 145 kDa found on 
B cells, some T cells and dendritic cells.  Its several ligands include CD19, CD23 and C3d.  
Like its major ligands, CD21 plays a key role in regulating B cell responses (Abbas and 
Lichtman 2001). 
 
CD25 is the alpha chain of the IL-2 receptor.  It is a glycoprotein of 55kDa that is 
expressed on activated T cells, B cells and monocytes.  When CD25 binds IL-2, it 
activates these cells (Abbas and Lichtman 2001).  Thus, CD25 is commonly considered a 
marker for activated T and B cells. 
 
CD26 is involved in signaling in T cells. 
 
CD45 is a family of 190 to 220kDa glycoproteins found on all cells of hematopoietic 
origin except red cells.  Alternative splicing of three exons generates various isoforms of 
CD45.  They are all phosphotyrosine phosphatases, some of which are required for 
signaling through the TCR. 
 
W.C.1 are a subset of gamma delta T cells, which are not homologous among species 
such as humans or mice.  The CD molecules have homology among domestic mammals 
as well as in humans and mice (Tizard 2000). 
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2.2 Leptin 
 
          Leptin is a hormone product of the obese gene originally identified in mice (Zhang 
et al. 1994).  It is a 16-kDa protein that is secreted almost exclusively by white adipocytes 
and then transported through blood and the brain barrier to the hypothalamus 
(Houseknecht et al 1998).  Leptin plays a central role in appetite regulation and energy 
expenditure (Zhang et al. 1994; Houseknecht et al. 1998; Buchanan et al. 2002).  Mice 
that are homozygous for the recessive mutation (ob/ob) in the obese gene do not express 
leptin.  Another fat mouse (db/db) homozygous for the recessive mutation is diabetic and 
has a defective receptor but is capable of producing leptin.  Both ob/ob and db/db mice 
are phenotypically similar with each weighing three times more than a normal mouse and 
having a fivefold increase in body fat (Friedman and Halaas 1998) 
          Leptin possesses a four-α-helix bundle structure that has identified it as a member 
of the haemopoietic cytokine family (Rock et al. 1996).  The structure of leptin bears 
close resemblance with the cytokine IL-6 (Tartaglia et al. 1996) that makes it an 
important factor in the regulation of immune response (Matarese et al. 2005).  In support 
of this, leptin receptors are not only found in the central nervous system but also in 
peripheral tissues such as hematopoietic and immune systems (Sanchez-Margalet et al. 
2003).  The cell types connected with immune and inflammatory response express the 
long form of leptin receptor, OB-R that allows leptin to adjust their response to diverse  
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stimuli.  Gainsford et al. (1996) also found that the CD4 and CD8 T -lymphocytes express 
the long form of the ob receptor.  Leptin also plays a role in reproduction.  The ob/ob 
mouse is infertile (Zhang et al. 1994) however administration of recombinant leptin to 
infertile ob/ob mice restores fertility (Chehab et al. 1996). 
 
 
2.2.1. Leptin and appetite regulation  
 
          Leptin regulates appetite and energy metabolism by decreasing food intake and 
increasing energy expenditure and physical activity (Houseknecht et al. 1998).  A higher 
body fat content results in an increased hypothalamic regulation of the secretion of leptin 
and vice versa.  Leptin is produced in the white adipose tissue and transported through 
the blood and brain barrier to the hypothalamus.  In the hypothalamus leptin binds to the 
long form of its receptors to elicit a neural response (Houseknecht et al. 1998).  The result 
of the neural response is an increased physical activity and energy expenditure and a 
decreased food intake.  This causes a reduction in the size of the adipose tissue, which 
later results in a negative feedback to inhibit further expression of the leptin gene 
(Houseknecht et al. 1998).  The expression of the ob gene is dependent on the level of 
energy stores and also on the size of the adipocyte.  It increases after food intake and 
decreases rapidly with food restriction (Waelput et al. 2002).  The leptin receptor (Ob-R) 
has five isotypes namely Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd and Ob-Re (Caprio et al. 2001).  
The Ob-Rb receptor, which is the longest form, is responsible for regulating appetite.  It 
is located in the hypothalamus (Caprio et al. 2001). 
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          Deficiency in leptin results in an obese phenotype with an increased appetite and a 
decreased metabolism.  The increase in appetite results partially from the inability of 
leptin to induce the secretion of alpha melanocyte stimulating hormone (α-MSH) from 
the hypothalamus.  One of the functions of α-MSH is to bind to central melanocortin-4-
receptor (MC4R) bearing neurons, which in turn reduces appetite (Figure 2.1).  This 
allows a diffusion of α-MSH to the periphery where upon binding to MC-Rs on 
adipocytes causes a mobilization of fat stores (Forbes et al. 2001).  There are five ways in 
which leptin reduces appetite.  This is illustrated in Figure 2.1. 
          Leptin reduces appetite by decreasing the levels of neuropeptide Y (NPY), an 
appetite stimulant (Houseknecht et al. 1998).  It increases the production of POMC, 
which then causes increased α MSH production (Pritchard et al. 2002).  Alpha MSH 
decreases appetite when bound to MC4R (Forbes et al. 2001).  Leptin also reduces the 
production of agouti related protein (AGRP), which functions to suppress MC4R 
(Pritchard et al. 2002).  This ability of leptin to increase the agonist (α-MSH) and reduce 
the antagonist (AGRP) results in α MSH possessing an advantage over AGRP for the 
receptor hence reducing appetite.  The production of leptin is also stimulated by 
glucocorticoids (Houseknecht et al. 1998). 
          In human obese subjects, this homeostasis is out of balance.  Possibilities are that 
adipocytes release large quantities of leptin, however, no α-MSH is released in response 
to it to bring about a reduced appetite (Forbes et al. 2001).  In the absence of central or  
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peripheral signaling of α-MSH, appetite increases.  The second possible reason for the 
obese subjects is that there is no functional leptin and this causes a less than sufficient 
amount of α-MSH to be released, hence contributing to high food intake (Forbes et al. 
2001). 
 Figure 2.1  Interaction between leptin and other hormones to reduce appetite. 
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CRH-Corticotrophin Releasing Hormone, AGRP-Agouti Related Protein 
NPY-Neuropeptide Y, MC4R-Melanocortin 4 Receptor 
 
 
Glucocorticoids stimulate the production of leptin (Houseknecht et al. 1998) and together 
with leptin they boost the production of POMC leading to the release of α-MSH.  When 
leptin is administered to leptin deficient (ob/ob) mice, peripheral α-MSH levels rise 
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leading to a high metabolic rate and an increase in weight loss through reduced food 
intake.  This indicates that α-MSH plays an important role in mediating appetite 
regulation in response to leptin (Forbes et al. 2001). 
          Leptin has been associated with fat deposition in cattle (Buchanan et al. 2002).  In 
cattle a single nucleotide polymorphism (SNP) i.e. a cytosine to thymine transition results 
in an amino acid change from arginine to cysteine was responsible for the increased 
carcass fat deposition (Buchanan et al. 2002).  The amino acid change is found on the 
fourth position from the N-terminus of the mature leptin protein molecule (Buchanan et 
al. 2002).  This is a beneficial non-conserved mutation for animal production since in 
dairy cattle a high milk and protein yielding animal increases profit.  In beef cattle, a 
premium is paid for marbling of muscle. 
 
2.2.2. Leptin and reproduction 
 
          Administration of leptin in both male and female ob/ob mice restored fertility but 
not in the db/db mice due to the defect in the receptor that led to the conclusion that 
obesity is not the cause of infertility but rather leptin deficiency directly modifies 
reproductive capacity (Chehab et al. 1996).  Leptin may directly affect the reproductive 
system or indirectly act on the reproductive system by regulating the secretion of growth 
hormone (GH) or prolactin (PRL), which then acts on the gonads as indicated in Figure 
2.2 (Clarke and Henry 1999; Adashi 1995; Linzer and Arey 1995).  Leptin affects  
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reproduction based on changes that occur in the amount of body fat (Clarke and Henry, 
1999).  In order to maintain a good reproductive function, normal levels of leptin are 
required and in humans this is also necessary for sustaining menstrual cycles as well as 
the prevention of amenorrhea (Mantzoros 2000). 
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Figure 2.2  Effects of leptin on the reproductive system (Adopted from Clarke and  
                   Henry, 1999).  GH-Growth Hormone, GnRH-Growth Hormone Releasing  
                   Hormone, L-Leptin, PRL-Prolactin 
 
 
 
          The peptide NPY is of importance to reproduction due to its effect on the gonads 
(Clarke and Henry, 1999).  NPY neurons have estrogen receptors that affect 
gonadotropin-releasing hormone (GnRH) and hence NPY suppresses luteinizing hormone 
(LH) secretion.  Plasma levels of leptin affect hypothalamic stimulation of the 
gonadotropic axis and hence sexual behavior (Aubert et al. 2002).  The secretion of 
Gonadotrophin Releasing Hormone-Luteinizing Hormone (GnRH-LH) in rats is 
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modulated by leptin.  Leptin affects reproduction by the release of luteinizing hormone 
(LH) in a pulsatile fashion similar to the release of the leptin hormone (Caprio et al. 
2001).  Aubert et al. (2002) concluded that in mice, leptin promotes sexual maturation but 
did not have a definite conclusion on experiments performed using other species such as 
rats, monkeys and humans. 
          Leptin must be above a critical threshold to induce sexual maturation, vaginal 
opening and increase in ovarian weight which results from the activation of the 
gonadotropic axis (Gruaz et al. 1998).  To initiate puberty leptin acts on the 
hypothalamus, hence leptin offers a permissive role with respect to puberty (Clarke and 
Henry 1999).  Leptin accelerates estrus and mating (Chehab 1997). 
          The concentration of leptin in the body increases during pregnancy but reduces 
during the latter stages of pregnancy and reaches its lowest level during lactation 
(Ingvartsen and Boisclair 2001).  In rats, leptin levels were highest between day 9 and 19 
of pregnancy-a two-fold difference compared to non pregnant mice and fell sharply to 
levels lower than non pregnant rats on day 21 just before parturition (Gruaz et al. 1998).  
The placenta produces leptin (Casabiell et al. 2001) hence leptin levels are higher in 
females than in males.  On the contrary, Gruaz et al. (1998) reported that the placenta 
does not produce leptin but is rather a target organ for leptin since it has a number of 
leptin receptors.  Maternal plasma leptin levels increases as pregnancy progresses due to 
over expression of leptin mRNA in both adipose tissue and placenta (Garcia et al. 2000). 
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2.2.3. Leptin and immune response 
          Leptin also regulates immunity (Ingvartsen and Boisclair 2001).  Leptin is secreted 
almost exclusively by white adipocytes (Houseknecht et al. 1998).  Leptin secretion is 
induced by lipopolysaccharides and cytokines (Faggioni et al. 1999).  Animals that either 
lack leptin (ob/ob) or are deficient of leptin receptors (db/db) have limitations in their 
immune and inflammatory reponses (Fantuzzi and Faggioni 2000).  Lord et al. (1998) 
found ob/ob mice to have defective cell mediated immunity.  Busso et al. (2002) 
observed that the ob/ob mice lymph node cells had a decreased interferon gamma (INF-γ) 
production.  ob/ob mice are more affected by the lethal effect of LPS compared to normal 
mice (Faggioni et al. 1999).  These limitations are also present in starved and 
malnourished animals, which are marked by low circulating leptin levels (Fantuzzi and 
Faggioni 2000). 
          A reduction in leptin level contributes to the adaptive response to preserve energy 
for the immediate vital functions of the body, which are required for survival (Waelput et 
al. 2002).  Significantly low leptin levels associated with restricted feed intake and low 
energy levels reduce the mRNA expression of the leptin gene in rat splenocytes (Lamas 
et al. 2004).  Reduced appetite and energy balance are linked with depressed immune 
function (Grunfeld et al. 1996).  This finding is in agreement with work done by Lord et 
al. (1998) in mice where the immunosuppressive effects of acute starvation have been 
overcome by supplying leptin. 
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          Leptin replacement restores normal immune response in ob/ob mice.  The 
restoration of the proper immune function in mice that had previously been starved is an 
affirmation of the interrelation between immune function and energy balance (Lord et al. 
1998).  Human leptin deficiency also causes a marked immune deficiency during 
starvation, which results in the suppression of a T-lymphocyte response.  This is a 
possible explanation for the increased sensitivity to infections when starved (Cason et al. 
1986).  Inherent leptin deficiencies in humans are causes of childhood infections and 
early mortality (Ozata et al. 1999). 
          Leptin mediates both innate and adaptive immunity.  In innate immunity, leptin has 
effect on monocytes and macrophages by up regulating their phagocytic role and also 
promotes the secretion of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-12 
(Matarese et al. 2005).  Leptin has a proliferating effect on human circulating monocytes 
in vitro.  The effect of leptin on adaptive immunity is through the production of 
lymphocytes that respond to peptide-major histocompatibility complexes as well as the 
production of survival signals for CD4 and CD8 lymphocytes during T lymphocyte 
maturation (Howard et al. 1999).  Leptin also increases the expression of activation 
markers such as CD25 (α-chain of IL-2 receptor) among others (Matarese et al. 2005).  
Leptin stimulates hematopoesis, T-cell immunity, phagocytosis and cytokine production, 
and also reduces susceptibility to infections (Ingvartsen and Boisclair 2001; Busso et al. 
2002). 
          Busso et al. (2002) found leptin to stimulate the growth of CD4 lymphocytes in 
vitro.  Leptin affects cytokine production as well as having proliferative and anti-
apoptotic effects on a diverse range of cell types including T lymphocytes, leukemia 
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cells, and hematopoietic progenitors (Fantuzzi and Faggioni 2000).  Leptin production is 
stimulated during infection and inflammation to activate monocytes and macrophages 
that function in innate immune response (Fantuzzi and Faggioni 2000).  Wound healing, 
angiogenesis (the formation of new blood vessels) and hematopoiesis are all 
characteristic of, and affected by leptin secretion (Fantuzzi and Faggioni 2000). 
          Leptin increases TH1 and decreases TH2 lymphocytes in mice (Ingvartsen and 
Boisclair 2001).  Similar results were obtained by Lord et al. (1998) who found ob/ob 
mice to have a shift toward TH2 cytokine production as well as having a defective cell 
mediated immunity.  Whilst leptin increases IL-2 and INF-γ production, it decreases IL-4 
production (Waelput et al. 2002).  This shows leptin’s role in regulating the TH1/TH2 
balance.  Large quantities of TH1 cytokines such as IL-2 and INF- γ are present in 
inflammatory lesions whereas TH2 cytokines, for example IL-4, are not.  In their study 
using mice with antibody-induced arthritis, Busso et al. (2002) found that the ob/ob mice 
lymph node cells had decreased INF- γ production, a TH1 cytokine, and an increased 
secretion of IL-10, a TH2 cytokine after being stimulated with methylated BSA in vitro.  
TH1 is a T-helper lymphocyte subset of CD4+ cells, which produces IL-2, INF-γ and 
TNF-α.  TH1 cells are very important in mediating phagocytotic killing of microbes 
(Abbas and Lichtman 2001).  Faggioni et al. (2001) also suggested that a defect in leptin 
production as found in the ob/ob mice might be associated with a shift of the immune 
response toward pro-inflammatory cytokines and a reduction in anti-inflammatory 
cytokines.  The expression of class II MHC molecules on macrophages is stimulated by 
INF- γ.  This action of INF- γ increases T-cell responses.  Leptin regulates the growth and 
rapid increase of naïve and memory T cells (Lord et al. 1998). 
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          Leptin activates monocytes to produce cytokines such as TNFα and IL-6 (Santos-
Alvarez et al. 1999).  The level of production of these cytokines depends on the quantity 
of leptin supplied.  In mice, Agnello et al. (1998) found that at doses higher than that 
required to cause body weight loss, leptin had the ability to induce IL-1 to stimulate the 
production of IL-6 and serum corticosterone in vivo.  They indicted that it is only at these 
high doses that leptin shows some of the in vivo activities associated with the IL-6 family 
of cytokines.  Leptin’s role as a pro-inflammatory cytokine has been illustrated in Figure 
2.3.  Leptin has the ability to activate T cells thereby leading to the production of IL-2, 
the T cell growth factor.  This results in further proliferation of T cells that attack infected 
body cells to kill them and remove the source of the infection. 
 
Figure 2.3  The role of leptin as a pro-inflammatory cytokine 
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          The effect of leptin on CD4+ proliferation has been tested in mice and it was 
observed that the cell population that had been preincubated with leptin for 12 hours had 
a marked increase in proliferation in the subsequent mixed-lymphocyte reaction (Lord et 
al. 1998).  The mixed-lymphocyte reaction was found to cause a proliferative response by 
both naïve and memory T cells. 
          Santos-Alvarez et al. (1999) found leptin to induce proliferation, differentiation and 
functional activation of hematopoietic cells.  The cytokine (TNF and IL-6) production by 
activated monocytes was measured.  The outcome showed that leptin administration 
produced an increased number of activated monocytes depending on its dose.  This 
indicates that leptin is a potent stimulatory hormone on human peripheral blood 
monocytes and suggests that it may also have a role as a proinflammatory cytokine 
(Santos-Alvarez et al. 1999; Sanchez-Margalet et al. 2003).  Faggioni et al. (1997; 1999) 
established that when leptin from an external source is supplied to leptin deficient mice, 
LPS and TNF-α induced lethality is forestalled.  In previous experiments, Gainsford et al. 
(1996) and Houseknecht et al. (1998) had indicated the ability of leptin to stimulate 
mature macrophages and to regulate hematopoiesis.  Leptin stimulates the growth of 
antibody-producing B-lymphocytes (Busso et al. 2002).  On the contrary, Agnello et al. 
(1998) suggested that the affect of leptin is more pronounced in the control of body 
weight but not in inflammatory or hematopoitic processes. 
          The effect of starvation on immune function is not always suppressive.  There 
seems to be an increased monocyte response because the activity of blood monocyte 
bacteria and natural killer cell cytolytic activity are enhanced by fasting (Wing et al. 
1983).  This was in agreement with the work done by Moriguchi et al. (1989) who  
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observed that macrophage function was enhanced by day two of starvation in mice but 
was suppressed at a longer term.  The number of peripheral blood monocytes increased in 
starved mice compared to fed mice.  This suggests that the proliferating population of 
monocytes could be the reasons for the resistance of the starved mice against infectious 
agents (Moriguchi et al. 1989). 
          Leptin has been shown to induce proliferative responses in vitro in mice (Waelput 
et al. 2002).  These responses are made possible using peripheral blood lymphocytes and 
highly purified CD4+ T lymphocytes as responders.  This observation is not present in  
db/db mice (Waelput et al. 2002).  Grunfeld et al. (1996) observed an increased leptin 
level and increased ob gene expression in adipose tissue following the administration of 
inflammatory stimuli, for example LPS or turpentine to hamsters. 
          Tumor Necrosis Factor is an important factor in the regulation of obesity by 
decreasing energy intake or inducing thermogenesis (Coombes et al. 1987, Rothwell 
1988).  Adipocytes of obese and morbidly obese patients over expressed TNF-α, which 
was proportional to the extent to which they were obese (Bullo et al. 2000).  This was 
also true in the work done by Hotamisligil et al. (1995) who found that the adipose tissue 
expression of TNF-α was positively related to BMI and decreased in proportion to the 
loss in body weight. 
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2.3. Pro-opiomelanocortin 
 
          Pro-opiomelanocortin (POMC) is a hormone derived in the hypothalamus (Arends 
et al. 1998) that is also processed in the cortitrophs of the anterior pituitary (Adachi et al. 
1999).  The POMC peptide which has a molecular weight of 32 kDa and serves as a 
precursor to several other biologically active peptides such as adrenocorticotropin 
(ACTH), beta-lipotropin, alpha-melanocyte stimulating hormone (α-MSH), beta- 
melanocyte stimulating hormone (β-MSH) and beta-endorphin, which are released by the  
pituitary glands of fish and mammals (Arends et al. 1998; Ali et al. 2005).  The basic 
function of POMC is to stimulate adrenal glands to release cortisol (Arends et al. 1998).  
In humans, the POMC gene maps to chromosome 2p23.3 (Chen et al. 2005) and to 
chromosome 11 in cattle (Thue and Buchanan 2003). 
          Pritchard et al. (2002) describe POMC’s role in the regulation of appetite (Figure 
2.1).  This role of POMC is linked with the bioactive peptides derived from pro-
hormones such as α-MSH and ACTH (Pritchard et al. 2002).  α-MSH regulates appetite 
and energy expenditure by binding to the melanocortin-4 receptor (MC4R) that is 
expressed mainly in the hypothalamus (Mori, 2001; Pritchard et al. 2002).  α-MSH or its 
analogues inhibits appetite whilst the MC4R antagonist agouti-related peptide (AGRP) 
stimulates appetite. 
          When MC4R is removed from adult mice, these mice tend to have a reduced 
energy utilization leading to obesity (Mori, 2001).  Humans and mice lacking POMC are 
obese and present hyperphagia as well as having adrenal insufficiency (Krude and 
Gruters 2000).  POMC neurons serve as important mediators in regulating feeding 
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behavior, insulin levels and body weight (Boston 2001).  This is consistent with the fact 
that POMC has a close link with appetite and obesity and hence qualified as a positional 
candidate gene for a growth quantitative trait locus in beef cattle (Thue and Buchanan 
2003).  Buchanan et al. (2005) have subsequently found an association between POMC 
and shipping weight, hot carcass weight and average daily gain in beef cattle. 
 
 
2.3.1. POMC and immune response 
 
          POMC derived α-MSH modulates some aspects of inflammation through direct 
effects on T cells, B cells and monocytes (Adachi et al. 1999).  The production of POMC 
peptides and POMC gene expression is under the stimulation of pro-inflammatory 
cytokines such as IL-1, IL-2, IL-6, INF-γ and TNF-α (Besedovsky et al. 1996).  
However, Adachi et al. (1999) found that although the activation of bone marrow 
cultured murine mast cells induced the expression of mRNAs for the inflammatory 
cytokines IL-1β, IL-4, IL-6, TNF-α, and the chemokine lymphotactin; mRNAs for IL-1 
β, TNF-α and lymphotactin were down-modulated in the presence of α-MSH.  This was 
consistent with the finding of Blalock (1999) in which the POMC product α-MSH 
functionally acts as an IL-1 antagonist.  Again, Getting et al. (1999) observed that in mice 
ACTH prevents neutrophil accumulation while peripheral blood cell count remained 
unchanged.  There was a similar occurrence with both α and β melanocyte stimulating 
hormones.  ACTH also significantly reduces chemokine release in vivo.  However, 
MC3R and MC4R both prevented this repressive effect of ACTH (Getting et al. 1999). 
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          The expression levels of peptides derived from POMC depend on immune cytokine 
release (Slominski et al. 2000).  Expression and release of POMC in the immune system 
is stimulated by CRH, but is inhibited by glucocorticoids (Bertagna et al. 1994).  Despite 
the inhibitory action of glucocorticoids on the pituitary gland, glucocorticoids increase 
POMC gene expression in the hypothalamus (Pritchard et al. 2002).  In rats, Mechanick 
et al. (1992) reported their inability to find POMC expression in either tissue-derived 
lymphocytes or peripheral blood mononuclear cells in vivo. 
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OBJECTIVE 
 
 To genotype 556 yearling beef cattle with single nucleotide 
polymorphisms (SNPs) in leptin and POMC in order to determine the 
correlation between genotypes with the numbers of B and T-
lymphocytes in these animals and their immune response to rabies 
vaccination. 
 
 
 
HYPOTHESES 
 
 SNPs in both leptin and POMC may have an influence on immune 
response in cattle since they have been speculated to be pro-
inflammatory cytokines. 
 
 There would be an association between the different genotypes (CC, 
CT, TT) of leptin and POMC, their lymphocyte population and the 
manner in which animals possessing these genotypes are able to 
respond to immune challenges.  Based on a previous study with leptin 
(Buchanan et al. 2002) we expect that the T allele may be linked with 
a better immune response. 
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3.0. MATERIALS AND METHODS 
 
3.1. Blood Collection and Vaccination 
 
          The blood samples, lymphocyte counts as well as rabies antibody concentrations 
were made available by the Western College of Veterinary Medicine at the University of 
Saskatchewan from a previous experiment in which a licensed commercial rabies vaccine 
had been administered to 556 healthy mixed breed yearling beef cattle.  These animals 
were selected from 27 beef herds in Alberta and Saskatchewan.  Animals had been 
vaccinated intramuscularly with two separate I M doses (2ml) of a killed, commercial 
rabies vaccine (IMRAB Bovine Plus, Merial Canada) on days 0 and 21 of the study 
period.  The study period was between March 13 and August 27, 2002.  Day 0 ranged 
between March 13 and May 15 for the various herds while day 42 ranged between April 
23 and August 27, 2002.  Sixty percent of these animals constituting 16 out of the total of 
27 herds received Bovine Viral Diarrhea Virus (BVDV) vaccination within one month 
prior to the investigation, or between day 0 and day 21.  Blood samples were collected 
just before vaccination on day 0 from each animal by jugular venipuncture to determine 
baseline serum rabies antibody titres.  The same method of blood collection was repeated 
on day 21 prior to administration of the booster vaccine and also on day 42 of the study.  
Blood samples were divided into 3; one was used for rabies antibody titre analysis, one  
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for lymphocyte subtype analysis and one for DNA analysis.  Blood samples that were 
used for DNA analysis were frozen at minus 80 degrees Celsius between the period of 
blood collection and DNA analysis.  Dan Bechtel of the Western College of Veterinary 
Medicine (WCVM) at the University of Saskatchewan as part of his PhD research 
performed the entire cell typing and coordinated the assessment of the rabies antibody 
measurements. 
 
 
3.2. Measurement of Rabies Antibody Titres 
 
           Rabies virus neutralizing antibody titres were determined at the Kansas State 
University Rabies Laboratory (Manhattan, KS, USA) using the rapid fluorescent focus 
inhibition test (RFFIT; Smith et al. 1973).  This test measures antibody directed against 
the glycoprotein antigen in the viral envelope, which prevents infection by the rabies 
virus and thus reflects the production of protective neutralizing antibodies. 
 
 
3.3. Lymphocyte Subtype Measurements Using Flow Cytometric Analysis 
 
          Flow cytometry was used to measure lymphocyte subtype populations with 
monoclonal antibodies (mAbs) using subtype-specific cell surface markers, followed by 
isotype-specific secondary fluorescent antibodies (Davis et al. 1995).  Previously 
determined titred dilutions of mAbs specific for lymphocyte subtype cell surface markers 
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were placed in triplicate (50μl per mAb dilution/well) into 96-well Falcon 7 U-bottom 
microtitre plates (Becton Dicinson, Franklin Lakes, NJ).  Prepared plates were made up 
in advance and were stored at 2-8oC for no more than one week.  One to two animals 
were randomly selected each week to act as negative controls in which cells were treated 
with either the primary mAbs or fluorescent secondary antibodies only, to ensure that 
background fluorescence, within a single fluorescence channel, remained below 1% of 
the total cell population. 
          A flow cytometer (Epics Elite ESP7, Beckman Coulter Inc., Mississauga, ON) was 
used to obtain data on the labeled cell types.  Data from 10,000 events per sample were 
acquired and subsequently analyzed using Expo327 acquisition and analysis software (v. 
1.2, Beckman Coulter Inc., Mississauga, ON).  Cell type proportions were converted to 
absolute cell counts before statistical analysis.  Either manual counting with a Neubauer 
hemocytometer (VWR International) or an automated cell counter (Cell Dyn 3500, 
Abbott Park, IL) was used to determine total white blood cell (WBC) counts.  Absolute 
cell counts were determined by first identifying neutrophils and monocytes, using the 
DH59B mAb. 
          The neutrophil population was gated using the side scatter (SSC) forward scatter 
(FS) dot plot to determine the granulocyte percentage.  Total percent positive cells were 
multiplied by absolute lymphocyte/monocyte counts as determined by subtracting the 
percent neutrophils, established with the flow cytometer, from the WBC count.  To  
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monitor differential accuracy, the percent neutrophils obtained from the flow cytometer 
was compared to the percent neutrophils obtained from manual differential WBC counts 
derived from blood smears (100 cell counts).  The analyzed cell types have been listed in 
Table 3.1. 
 
Table 3.1 Cell Types Analyzed 
CD4    CD4CD25CD45
CD8    CD4CD26CD45
Ratio of CD4 to CD8    CD8CD25CD45
W.C.1 cells    CD8CD26CD45
Gamma delta cells     CD5CD21 & B cells 
IL-2    B cells 
 
 
 
 
3.4. DNA Extraction and Genotyping 
 
          DNA was extracted from frozen whole blood samples (n=556).  DNA extraction 
was initially performed by salt extraction (Montgomery and Sise 1990) for about half of 
the total number of samples and by a phenol-chloroform method (Sambrook et al. 1989) 
for the remaining half.  The entire set of extracted DNA was purified using the MagNa  
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 pure LC kit (Roche Molecular Biochemicals, Mannheim, Germany).  Polymerase Chain 
Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) tests were run for the 
SNPs in LEP (Buchanan et al. 2002) and POMC (Thue and Buchanan 2003). 
 
 
3.4.1. Leptin-PCR-RFLP 
 
          Each reaction (20μl) was made up of: 10 pmoles of forward and reverse primers, 1 
U Taq DNA polymerase (Invitrogen), 200 μM dNTPs, 10X PCR buffer, 1.5 mM MgCl2 
(Invitrogen), sterile distilled water and approximately 30 ng of genomic DNA.  PCR 
amplification had an initial denaturation at 94oC for 2 minutes, followed by 35 cycles of 
94oC for 45 s, 52oC for 45s, and 72oC for 55s.  Final extension was set at 72oC for 3 min. 
          A test gel (0.7% agarose) was routinely run for each batch of samples after each 
PCR using 5 μl of PCR product.  Each digestion reaction consisted of 15 μl of PCR 
product, 2 U of Kpn 2I (MBI Fermentas), 10X Y+/Tango buffer and sterile distilled 
water.  A total reaction volume of 20 μl was incubated at 55oC overnight and DNA 
fragments were separated on 3% agarose gel by electrophoresis. 
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3.4.2. POMC-PCR-RFLP and Real Time PCR 
 
          Each 20μl reaction contained: 10pmoles of forward and reverse primers, 200 μM 
dNTPs, Jeffrey’s buffer (4.5 mM MgCl2), DMSO, sterile distilled water, 1 U Taq DNA 
polymerase (Invitrogen), and approximately 30 ng of genomic DNA.  PCR amplification 
had an initial denaturation at 94oC for 2 minutes, followed by 35 cycles of 94oC for 1min; 
52oC for 45s, and 72oC for 1min.  Final extension was set at 72oC for 3 min. 
          A test gel (0.7% agarose) was run after each PCR using 5 μl of PCR product. 
Each digestion reaction consisted of 15 μl of PCR product, 2 U of Bts I restriction 
endonuclease, 10X NEBuffer 4 and sterile distilled water.  A total reaction volume of 20 
μl was incubated at 37oC overnight and DNA fragments were separated on 2% agarose 
gel by electrophoresis. 
          Samples that failed to amplify for POMC (n=51) were analyzed at Quantum 
Genetics using real time capillary PCR via a LightCycler 1 (Roche Molecular 
Biochemicals, Mannheim, Germany).  The primer sequences used were: - 
Forward primer: - 5’GAT GAG CAG CCG CTG ACT 3’ 
Reverse primer: - 5’GTC AGC TCC CTC TTG AAT TCG AG 3’ 
Sensor probe: - 5’CAA CTC CGC TGC TGC TGC 3’ 
Anchor probe: - ACC ATT CCG ACG GCC GAA GC 3’ 
The PCR reaction (10.3 μL) comprised distilled water, 2.9 mM MgCl2, 6 pmol of forward 
primer and reverse primer, 5 pmol per reaction of anchor probe, 5 pmol per reaction of 
sensor probe and 0.7 μL of LightCycler FastStart DNA master hybridization probes 
(catalog no. 2 239 272; Roche Molecular Biochemicals, Mannheim, Germany) plus 1 μL  
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of sample template DNA.  The anchor probe was labeled with flourescein as the donor, 
and the sensor probe was labeled with LightCycler Red 640 (TIB Molbiol LLC, 
Adelphia, NJ) as the acceptor for the FRET reaction. 
          The PCR fluorescence resonance energy transfer (FRET) conditions included an 
amplification program beginning with denaturation at 95oC for 10 min, followed by 45 
cycles of 95oC for 2s, 60oC for 10s, and 72oC for 14s.  The melting program of the 
reaction was heated to 95oC and then cooled to 40oC over 120s followed by a continuous 
increasing temperature transition rate of 0.2oC/s until a temperature of 75oC is reached. 
          The cooling portion of the reaction is lowering the temperature to 40oC for 5s.  
Melting temperatures ™ were derived from melting peaks using LightCycler software 
version 3.5. Each test batch incorporated a maximum of 28 samples plus three positive 
controls (CC, CT and TT) and a negative control (water). 
 
 
3.5. Statistical Analysis 
 
          The primary null hypothesis was that there was no association between the 
immunological outcome (lymphocyte numbers and change in rabies antibody titres from 
day 0 to day 42) and genotype.  Descriptive statistics were completed using SPSS for 
Windows (version 11.5.0, SPSS Inc. Chicago, IL, USA).  Transformation of the outcome 
variables was used to improve the normality of the residuals.  Dr Cheryl Waldner of the 
WCVM, University of Saskatchewan performed the statistical analysis while I extracted 
the relevant information and interpreted the results. 
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          The potential association between genotype and immune function parameter was 
explored sequentially using a mixed linear model (PROC MIXED, SAS version 8.2, SAS 
Institute, Cary, N.C., USA).  Clustering outcomes at the herd level was accounted for 
with random intercept for herd.  Each association was examined in a model adjusted for 
herd effects and cell counting method in compliance with rabies vaccination protocol.  
The adequacy of the models was evaluated using normal probability plots of the residuals 
and plots of residuals against predicted values to verify that the assumptions of normality 
and homogeneity of variance had been met. 
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4.0 RESULTS 
 
4.1 Leptin 
 
          Results were obtained from a number of cattle used for this research, which were 
556 on day 0 and 443 on day 42 for leptin.  The subjects for POMC were 519 on day 0 
and 415 on day 42. A representative photograph of a leptin PCR-RFLP gel is shown in 
Figure 4.1.  An uncut product is visible at approximately 95 base pairs (bp) indicating a T 
allele whilst cut products representing a C allele have bands at 75bp and 19bp (not 
usually visible on gel).  Lane 9 is from an animal homozygous for C allele, lane 13 is 
from an animal homozygous for T allele and the rest of the animals on the gel are 
heterozygotes. 
 
 
 
Figure 4.1  PCR-RFLP gel showing genotypes of leptin.  Lane 1, 100bp ladder.  Bands at  
                   95bp represent the T allele and bands at 75bp represent C allele. 
 
          Allele frequencies for leptin on both day 0 and day 42 are shown in Table 4.1.  
There was not much difference between the allele frequencies for the two visits.  The 
results from the Proc mixed analysis of leptin genotypes with immune data are presented 
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in Tables 4.2 and 4.3.  These represent the outcomes that have probabilities less than or 
equal to 0.1 (P ≤ 0.1) on days 0 and 42 respectively.  Least square means per genotypes 
with outcomes (P ≤ 0.05) are illustrated in Figures 4.2 and 4.3 respectively for day 0 and 
day 42. 
 
Table 4.1  Allele frequencies for leptin 
Allele C T N Frequency 
Day 0 644 468 556 C = 0.58 
T = 0.42 
     
Day 42 530 356 443 C = 0.60 
T = 0.40 
 
   
          On day 0 (Table 4.2 and Figure. 4.2) there were only two cell types that had 
significant variations with leptin genotype: the activated CD4 and the activated CD8 cells.  
Cattle with TT genotypes had a significantly higher number of the activated CD4 cells 
than those homozygous for the C allele (P = 0.036).  There was a trend with the CT 
animals having a lower number of activated CD4 cells compared to the TT animals (P = 
0.095).  The same association was true for the CD8_25_45 activated CD8 cells.  Animals 
homozygous for the C allele had fewer activated CD8 cells compared to the TT animals 
(P = 0.05).  Hence, for day 0, the animals with the TT genotypes seemed to have higher 
numbers of activated T lymphocytes. 
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Table 4.2   Relationship between leptin genotypes and numbers of immune cell types 
                  On day 0 
Cell Type Genotype Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% C.I 
P-Value
Log Activated CD4 (CD4_26_45) CC-TT -0.063 -0.123 -0.004 0.036 
 CT-TT -0.045 -0.098 0.008 0.095 
 CC-CT -0.018 -0.055 0.019 0.330 
Log Activated CD8 (CD8_25_45) CC-TT -0.058 -0.117 -0.000 0.050 
 CT-TT -0.043 -0.095 -0.009 0.106 
 CC-CT -0.015 -0.052 0.021 0.401 
 
C.I refers to Confidence Interval 
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Figure 4.2  Least square means of immune cell types found in peripheral blood in beef        
         cattle having significant variation with leptin genotype on day 0. 
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          Variations in cell counts with respect to leptin genotypes on day 42 (Table 4.3 and 
Figure 4.3) were seen in seven cell types, namely; regular CD4, activated CD4, CD8_25_45 
activated CD8, CD8_26_45 activated CD8 cells, ratio of CD4 to CD8 cells, gamma delta cells 
and W.C. 1 cells.  Animals with TT genotype had a trend showing elevated numbers of 
regular CD4 cell count compared to both the CT animals and the CC animals. 
 
Table 4.3  Relationship between leptin genotypes and numbers of immune cell types 
                  On day 42 
Cell Type                 
Genotype    
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% C.I 
P-Value
Log regular CD4 cells CC-TT -0.043 -0.094 0.008 0.095 
 CT-TT -0.044    -0.091 0.003 0.067 
 CC-CT 0.001 -0.029 0.030 0.967 
Log Activated CD4 (CD4_26_45) CC-TT -0.016 -0.085 0.053 0.651 
 CT-TT -0.054 -0.118 0.010 0.098 
 CC-CT 0.038 -0.002 0.078 0.062 
Log Activated CD8 (CD8_25_45) CC-TT -0.022 -0.087 0.043 0.499 
 CT-TT -0.061 -0.121 -0.000 0.048 
 CC-CT 0.038 0.001 0.076 0.046 
Log Activated CD8 (CD8_26_45) CC-TT 0.002 -0.069 0.072 0.961 
 CT-TT -0.042 -0.107 0.023 0.202 
 CC-CT 0.044 0.004 0.085 0.033 
Log Ratio of CD4to CD8 CC-TT -0.026 -0.070 0.018 0.245 
 CT-TT -0.003 -0.043 0.037 0.884 
 CC-CT -0.023 -0.048 0.002 0.075 
Log CD8 gamma delta cells CC-TT 0.009 -0.052 0.069 0.780 
 CT-TT -0.039 -0.095 0.017 0.173 
 CC-CT 0.048 0.013 0.083 0.007 
Log W.C.1 cells CC-TT -0.096 -0.179 -0.014 0.023 
 CT-TT -0.054 -0.130 0.023 0.169 
 CC-CT -0.043 -0.090 0.005 0.079 
 
C.I refers to Confidence Interval           
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          With respect to the activated CD4 cells, the animals homozygous for the T allele 
again had a higher cell count compared to the CT animals. However, the homozygous C 
animals also had higher activated CD4 counts than the CT animals.  A similar pattern was 
seen in the CD8_25_45 activated CD8 cells.  Here again, the TT animals had significantly 
higher number of cells compared to the CT animals and the homozygous C animals had 
higher cell numbers than the CT animals (P = 0.048; P = 0.046) respectively.  With the 
CD8_26_45 activated CD8 cells the CC animals again had a higher cell count than their CT 
counterparts. 
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Figure 4.3  Least square means of immune cell types found in peripheral blood in beef                          
        cattle having significant variation with leptin genotype on day 42 
        gd cells = gamma delta cells 
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          The ratio of CD4 to CD8 cells was higher in CT animals than in animals 
homozygous for the C allele.  Animals homozygous for the C allele had a higher gamma 
delta cell count relative to the CT animals.  Animals homozygous for the T allele or  
heterozygous had higher counts of W.C. 1 cells compared to the animals homozygous for  
the C allele (P = 0.023; P = 0.079) respectively.  Comparisons among genotypes were 
made for all the other cell types and have been listed in Appendix A.  Only results that 
had P values less than 0.1 have been discussed.  
 
4.2. Antibody Titres 
 
          The differences between the rabies antibody titres for the three visits were 
measured.  While there were significant variations in the rabies antibody titres between 
days 0 and 21 or 42 among genotypes of leptin (Table 4.4. and Figure 4.4), there was no 
such variation among genotypes of POMC for any of the 3 visits.  All results of rabies 
antibody titre measurements for POMC as well as that for leptin have been indicated in 
Appendix B and those having P values less than 0.1 have been discussed. 
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Table 4.4 Rabies antibody titres versus corresponding genotypes of leptin 
 
 
Day Genotype Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% C.I 
P-Value
Logdiff0to21  CC-TT 0.137 -0.015 0.290 0.078 
 CT-TT 0.141 0.002 0.280 0.047 
 CC-CT -0.004 -0.098 0.091 0.940 
Logdiff0to42 CC-TT 0.188 0.009 0.367 0.039 
 CT-TT 0.179 0.014 0.345 0.034 
 CC-CT 0.009 -0.095 0.113 0.866 
 
Logdiff0to21 refers to the logarithm of differences in rabies antibody titres on day 0 and 
day 21 
Logdiff0to42 refers to the logarithm of differences in rabies antibody titres on day 0 and 
day 42 
 
C.I. refers to Confidence Interval 
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Figure 4.4  Least square means of rabies antibody titres in peripheral beef cattle blood                              
        with significant variation with leptin genotype  
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Within a short period, i.e. within the first twenty-one days, there was a significant 
difference in the rabies antibody titres of the CT animals in relation to the TT animals.  
The titres of the CT animals were significantly higher than those of the TT animals while 
there was a trend with CC animals having higher titres than those of the TT animals. 
          Over a longer period, i.e. between day 0 and day 42, there was again a significant 
difference between the titres of the CT animals and those of the TT animals as well as a 
significant difference between the titres of the CC animals and the TT animals.  Both the  
titres of the CT and CC animals were significantly higher than those of the TT animals.  
There was no measurable difference in the response to the second vaccination (day 21-
day 42) associated with genotype (Appendix B). 
 
 
4.3 Pro-opiomelanocortin 
 
          Figure 4.5 is representative of a PCR-RFLP gel of POMC alleles.  An uncut 
product is visible at 390 bp indicating a C allele whilst a cut product represents the T 
allele with products of 233bp and 157bp.  Lanes 3, 5-7 are CCs, lanes 8 and 9 are TTs.  
Remaining lanes are CTs. 
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Figure 4.5  PCR-RFLP gel showing genotypes of POMC.  Lane 1, 100 bp ladder.   
Band at 390 bp represents the C allele and bands at 233 bp and 157 bp               
represents the T allele. 
 
The allele frequencies of POMC for both day 0 and 42 are presented in Table 4.5.  
Although the relative gene frequency remained very similar, some animals were not 
available for study on day 42.  The association between POMC and immune system 
outcome are reported for days 0 and 42 in Tables 4.6 and 4.7.  The presented outcomes 
have probabilities of less than 0.1 (P ≤ 0.1).  Least square means per genotypes (P ≤ 0.05) 
are graphed for day 0 in Figures 4.6 and 4.7 for day 42.  The differences among 
genotypes of POMC were compared for all the other cell types and have been listed in 
Appendix C while results with P value less than 0.1 have been discussed. 
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Table 4.5  Allele frequencies for pro-opiomelanocortin 
 
Allele C T N Frequency 
Day 0 767 271 519 C = 0.74 
T = 0.26 
     
Day 42 610 220 415 C = 0.73 
T = 0.27 
 
 
 
 
 
          On day 0, the changes in cell count in relation to the different genotypes of POMC 
occurred in seven cell types (Table 4.6).  The cells involved were the activated CD4, 
regular CD8, CD8_25_45 activated CD8, CD8_26_45 activated CD8, ratio of CD4 to CD8 cells, 
the combination of CD5CD21 and B cells and B cells.  Figure 4.6 represents the least 
square means per genotype of cell types with P ≤ 0.05 on day 0.  The animals responded  
in a similar pattern with activated CD4, regular CD8, and CD8_25_45 activated CD8 cells.  
In all of these three cell types, the CT animals had a tendency for higher cell numbers 
compared to the TT animals while CT animals had significantly higher numbers of these 
cells compared to CC animals. 
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Table 4.6  Relationship between POMC genotypes and numbers of immune cell types on 
       day 0 
 
Cell Type                 
Genotype    
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% C.I 
P-Value
Log Activated CD4 (CD4_26_45) CC-TT 0.001 -0.063 0.065 0.966 
 CT-TT 0.059 -0.004 0.122 0.065 
 CC-CT -0.058 -0.095 -0.021 0.002 
Log CD8  (regular CD8 cells) CC-TT 0.015 -0.039 0.070 0.580 
 CT-TT 0.048 -0.006 0.101 0.083 
 CC-CT -0.032 -0.064 -0.001 0.046 
Log Activated CD8 (CD8_25_45) CC-TT 0.008 -0.055 0.070 0.812 
 CT-TT 0.058 -0.003 0.120 0.064 
 CC-CT -0.051 -0.087 -0.014 0.006 
Log Activated CD8 (CD8_26_45) CC-TT 0.001 -0.068 0.070 0.983 
 CT-TT 0.034 -0.033 0.102 0.318 
 CC-CT -0.034 -0.073 0.006 0.095 
Log Ratio of CD4 to CD8 CC-TT -0.020 -0.062 0.023 0.364 
 CT-TT -0.042 -0.084 0.000 0.051 
 CC-CT 0.022 -0.002 0.047 0.077 
Log CD5CD21 & B cell CC-TT 0.058 -0.006 0.123 0.077 
 CT-TT 0.037 -0.027 0.101 0.256 
 CC-CT 0.021 -0.016 0.059 0.266 
Log B cell CC-TT 0.017 -0.053 0.073 0.553 
 CT-TT -0.019 -0.074 0.037 0.509 
 CC-CT 0.035 0.003 0.068 0.032 
 
C.I refers to Confidence Interval 
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Figure 4.6  Least square means of immune cell types found in peripheral blood in beef  
        cattle having significant variation with POMC genotype on day 0. 
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The CT animals had a higher number of CD8_26_45 activated CD8 cells compared to the 
animals with homozygous C genotype.  Animals homozygous for the T allele had a 
higher ratio of CD4 to CD8 cells compared to the CT animals.  However, the CC animals 
were higher than the CT animals in that same cell count.  With the combination of 
CD5CD21and B cell count, the homozygous C animals were higher than the homozygous 
T animals.  B cell count was higher in animals with CC genotype than those with CT 
genotype (P = 0.032). 
          On day 42, five cell types varied (P ≤ 0.1) with the POMC genotype (Table 4.7); 
two of these had P ≤ 0.05.  Figure 4.7 indicates the graphed least square means of the two 
cell types.  The CT animals had elevated counts of activated CD4, CD8_25_45 activated 
CD8, and CD8_26_45 activated CD8 cells over the CC animals.  The TT animals maintained 
a higher ratio of CD4 to CD8 cell count over CT animals (P = 0.043).  Animals 
homozygous for the C allele also maintained a higher B cell count relative to the CT 
animals. 
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Table 4.7  Relationship between POMC genotypes and numbers of immune cell types on 
       day 42 
 
Cell Type                 
Genotype    
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% C.I 
P-Value
Log Activated CD4 (CD4_26_45) CC-TT -0.020 -0.096 0.055 0.599 
 CT-TT 0.019 -0.056 0.093 0.619 
 CC-CT -0.039 -0.081 0.003 0.069 
Log Activated CD8 (CD8_25_45) CC-TT -0.005 -0.075 0.066 0.894 
 CT-TT 0.029 -0.040 0.099 0.408 
 CC-CT -0.034 -0.073 0.005 0.090 
Log Activated CD8 (CD8_26_45) CC-TT -0.009 -0.085 0.067 0.812 
 CT-TT 0.034 -0.041 0.109 0.376 
 CC-CT -0.043 -0.085 -0.001 0.047 
Log Ratio of CD4 to CD8 CC-TT -0.030 -0.077 0.017 0.206 
 CT-TT -0.047 -0.093 -0.002 0.043 
 CC-CT 0.017 -0.008 0.043 0.186 
Log B cell CC-TT 0.008 -0.052 0.067 0.802 
 CT-TT -0.024 -0.083 0.035 0.430 
 CC-CT 0.031 -0.002 0.065 0.064 
 
C.I refers to Confidence Interval 
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Figure 4.7  Least square means of immune cell types found in peripheral blood in beef  
        cattle having significant variation with POMC genotype on day 42.  
  
 
 
          Descriptive statistics and least square means were calculated for all the immune 
cells types that were affected by leptin and POMC.  These results have been tabulated in 
appendices D and E respectively.  However, least square mean calculations made for the 
cell types that had significantly different outcome among the various genotypes have 
been indicated above in graphs. 
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5.0. DISCUSSION 
 
5.1. Data Collection 
 
          The difference in the number of animals sampled was a result of the cattle owners’ 
inability to keep all the animals throughout the period of the research.  Hence, some of 
the animals that were tested on day 0 were not available for testing on day 42.  Some of 
the animals had been sold or put out to pasture with the bull.  A number of the herd 
owners did not want to sample the heifers after the start of the breeding season.  The herd 
owners were concerned about the effect of stress on conception rates.  For this reason, the 
initial twenty-seven herds that were sampled on day 0 were reduced to twenty-one on day 
42. 
          The twenty-seven herds sampled on day 0 were part of a larger study of immune 
function in beef cattle.  For leptin, on day 0, the herd comprised twenty-three (23) bulls 
and five hundred and thirty three (533) heifers.  For POMC, there were twenty-three (23) 
bulls and four hundred and ninety six (496) heifers.  However on day 42, all the animals 
for which measurements were taken were heifers and this was also true for subjects used 
for rabies antibody titres.  Of relevance to this research was the immune cell counts for 
day 0 and day 42, and the rabies titres for all three visits i.e. day 0, 21 and 42.  It should 
also be noted that this study is a reflection of occurrences in vivo and the results were 
drawn from several farm herds.  The outcome may serve as a guide to the natural 
environment as opposed to the available literature that are mainly based on in vitro 
studies. 
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5.2. Leptin 
 
          The presence of a significantly higher number of activated CD4 and CD8 cells in 
the animals with TT genotypes for leptin on day 0 could have been due to a sub-acute 
infection in all the animals for which the immune cells had been activated to combat.  In 
the presence of an infection, immune cells are activated to eliminate the microbes.  After 
the elimination of the microbes, a reservoir of immune cells, the memory cells, remain 
that function as the first cells to fight disease pathogens in subsequent infections (Abbas 
and Lichtman 2001). 
          The difference in the association between leptin and lymphocyte numbers from day 
0 to day 42 was considered a reflection of the effect of the rabies vaccine on the animals 
within that period.  Other factors that could also be associated with this difference include 
changes to the nutritional status of herds during this period and pre-breeding vaccination 
for BVDV and infectious bovine rhinotracheitis (IBR).  For leptin, animals with TT 
genotypes maintained a higher number of activated CD4 cells than CT animals, which 
was consistent with day 0.  Gainsford et al (1996) and Lord et al (1998) reported that 
naïve and memory T cells are differentially affected by leptin, which mainly regulates 
primary T cell responses.  In an in vitro study where the effect of leptin on CD4 
proliferation was tested, it was observed that the cell population that had been pre-
incubated with leptin for 12 hours had a marked increase in proliferation in the 
subsequent mixed lymphocyte reaction (Lord et al. 1998). 
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          The CC animals had significantly elevated number of activated CD8 cells.  This 
was not consistent with the occurrence on day 0.  Although available literature do not 
indicate leptin’s ability to influence CD8 cells, Busso et al. (2002) found leptin to 
stimulate the proliferative response of CD4 T cells in the context of mixed lymphocyte 
reaction in vitro.  Since both CD4 and CD8 cells are subsets of T cells, it is assumed that 
leptin might also stimulate the production of CD8 cells.  The animals with TT genotypes 
also maintained a higher number of CD8CD25CD45 activated CD8 cells.  This was again 
consistent with the concept of leptin’s ability to stimulate proliferative response of CD4 T 
cells (Busso et al. 2002).  The CC animals had an increased number of activated CD4 
cells over the CT animals.  A similar situation occurred with the CD8CD26CD45 activated 
CD8 cells of the CC animals, which was again significantly higher than that of the CT 
animals on day 42.  Animals with CT genotypes had a higher ratio of CD4 to CD8 cells, 
which confirms the outcome of the activated CD4 and CD8 cells without making 
reference to the ratio.  In leptin, a change from cytosine (C) to thymine (T) changes the 
amino acid from arginine to cysteine (Buchanan et al. 2002).  It was expected that one 
allele could consistently be associated with increased number of immune cells.  Based on 
a previous study with leptin, where the T allele was associated with increased linear 
somatic cell count in dairy cattle (Buchanan et al. 2003), the anticipation was that the T 
allele might be the one to have that connection. 
          In addition to the activated CD4 and CD8 cells, the CC animals also had a 
significantly higher number of CD8 gamma-delta cells, a subset of T lymphocytes with 
receptors that recognize lipids and non-peptide antigens displayed by molecules other 
than MHC molecules.  They are abundant and function in the epithelial surfaces.  The 
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increased number of regular CD4 cells in the TT animals as compared to both CC and CT 
animals was expected based on the outcome of day 0.  In previous studies with leptin, the  
T allele has been associated with increased linear somatic cell count in dairy cattle 
(Buchanan et al. 2003).  This may reflect a role in immune response since it was the high 
milk yielding cattle that also had increased somatic cell count and part of the components 
of somatic cells are white blood cells as well as other immune cells.  Animals with TT 
and CT genotypes had an elevated number of the W.C. 1 cells, a subset of T cells on day 
42. 
 
 
5.3. POMC 
 
          The expression of the POMC gene in the hypothalamus is partially regulated by 
leptin (Mori 2001).  It is therefore possible that the POMC genotype will influence 
immune cell counts.  The SNP in POMC however, does not change the amino acid; the 
amino acid remains serine whereas in the case of leptin, a change from cytosine (C) to 
thymine (T) changes the amino acid from arginine to cysteine (Buchanan et al. 2002).  
Hence, although there was an expected association in the case of POMC, the beneficial 
allele could not be predicted.  The results for POMC on day 0 showed that animals with 
CT genotypes had a significantly (P = 0.02) higher number of activated CD4 cells than 
the CC animals.  The CT animals again showed a trend of higher activated CD4 cells over 
the TT animals.  The CT animals also had a higher number of regular CD8 cells than TT 
animals (P = 0.083) and CC animals (P = 0.046). 
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           The situation was not any different with both the CD8CD25CD45 and 
CD8CD26CD45 activated CD8 cells.  Animals with CT genotypes had higher numbers of 
these cells compared to both the CC and TT counterparts.  TT genotypes had a 
significantly higher CD4 to CD8 cell ratio than their CT counterparts.  However, there 
was a trend with the CC animals having a higher CD4 to CD8 ratio cell counts than the 
animals with CT genotypes.  With the CD5CD21and B cell, the animals with CC 
genotypes had a trend for higher immune cell count than the TT animals.  The CC 
animals however had a higher number (P = 0.032) of B cells than the animals with CT 
genotypes. 
          Day 42 is of more physiological and immunological significance because of the 
response of the animals to the rabies vaccine although other factors such as the BVDV 
and nutrition might also be playing some roles.  The effect of the vaccine was manifested 
in four of the immune cell types, which were: the activated CD4, CD8CD25CD45 and 
CD8CD26CD45 activated CD8 cells and B cells.  Adachi et al. (1999) found α-MSH, a 
POMC derived neuropeptide, to down modulate some aspects of inflammation through 
direct effects on T-lymphocytes, B-lymphocytes and monocytes.  This was true in the 
outcome of this research.  Animals with TT genotypes had a significantly elevated CD4 to 
CD8 cell type ratio (P = 0.043).  The CD8CD26CD45 activated CD8 cell counts for animals 
with a CT genotype were also significantly (P = 0.047) high.  In all, the effect of POMC 
in modulating inflammation through direct effects on T and B cells was manifested. 
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5.4. Possible Causative Factors of Variations in Outcome 
 
          Generally, the number and type of cell did not follow a clear pattern for the various 
genotypes of animals.  There were inconsistencies in the outcome.  In some instances, 
animals with the T allele produced more of a particular immune cell type whilst animals 
with the C allele produced an elevated level of other immune cell types.  Several factors 
could have come into play to result in this occurrence including nutrition.  Since animals 
used in this research were from different herds, there is the possibility of nutritional 
variations. 
          Deficiencies or excessive use of trace minerals in animal rations could result in 
discrepancies in the immune functions of these animals.  Minatel and Carfagnini (2000) 
observed that in ruminants copper deficiency results in a change in the production of 
acute phase proteins.  They also noted that in ruminants, copper deficiency affects 
components of the innate immune response especially the production of neutrophils, even 
though there is no established finding about the effect of copper on macrophage 
production (Minatel and Carfagnini 2000).  Graham (1991) also found that in cattle 
selenium deficiency results in immune dysfunction causing changes in the normal 
immunoresponsiveness or control of inflammation.  Selenium deficiency also causes a 
reduced mixed lymphocyte reaction and a reduced responsiveness to interleukin 1 (IL-1) 
and interleukin 12 (IL-12).  Zinc deficiency affects humoral immunity by altering 
antibody formation and affects cellular immunity by reducing responsiveness to 
interleukins (Graham 1991).  According to his findings, zinc deficiency also changes 
macrophage and neutrophil function. 
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          The source of dietary lipids could also be a contributing factor to the animals’ 
ability to resist diseases.  Drouillard et al. (2001) observed that feeding flaxseed to cattle 
could positively influence both growth performance and immunity.  The results of their 
research indicated that cattle fed flaxseed produced more TNF-α and had a higher total 
white blood cell count compared to those fed either tallow or soybean as a dietary source 
of lipid. 
          It should however be noted that the occurrence of a high immune cell output in an 
animal does not make it better.  This is because animals may be responding to other 
challenges and not necessarily to the challenge in question.  Also, up regulating one cell 
type in an animal may result in the down regulation of other cell types and might have 
potential effects on cytokines as well.  For instance, TH1 cytokines such as IL-2 and TH2 
cytokines such as IL-4 work differently (Abbas and Lichtman 2001); TH2 down regulates 
TH1 responses.  Since cytokines are pleiotropic in nature, the outcome of this project 
might not be wholly attributable to leptin and/or POMC.  These results are representative 
of cell types appearing only in the blood of the animals.  No measurements were taken 
from the bone marrow, lymph nodes, spleen or any body cells of the animals. 
          DNA extraction was from frozen blood that had been stored at minus 80 degrees 
Celsius for nearly a year.  DNA had to be purified by the MagNa Pure kit as a result of 
poor amplification.  The use of fresh blood might potentially limit or exclude such poor 
amplification suspected to be due to inhibitors present in the DNA.  Counting of the 
lymphocyte subtypes would have been more uniform by just using one method of  
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counting instead of using both manual and mechanical counting methods.  It is also 
suggested that in future research, animals in the same herd be used to ensure that sources 
of variations such as that of management are minimized. 
 
 
5.5. Rabies Antibody Titres 
 
           Rabies titres were measured on days 0, 21 and 42 and the differences between 
them were evaluated.  There was a significant response to vaccination in all animals.  For 
leptin, the significant increase in the rabies titres, which occurred within the first 21 days, 
was expected.  This is because generally, when animals are vaccinated their immune 
system is activated to produce immune cells.  T cells, B cells and macrophages are all 
required for maximal antibody production against most antigens.  It takes about three 
days to detect anti-rabies immunoglobulin M after vaccination and seven to fourteen days 
to detect peak antibody titres (Dietzschold et al. 1978).  The glycoprotein of the rabies 
virus is the only varion component that induces the production of, and reacts with 
neutralizing antibodies and that protects animals from challenge (Wiktor et al. 1973).  
Dietzshold et al. (1978) supported this finding and added that the antibodies raised 
against purified rabies virus glycoprotein have been shown to neutralize infectious rabies 
virus and the purified glycoprotein was more immunoprotective when used alone. 
          The effect of the booster vaccine administered on day 21 was seen in all the 
animals however; there was no association between genotype and the increase in 
antibody concentration in response to the second rabies vaccination.  However, the 
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overall difference (log diff 0 to 42) was significantly higher in both CC and CT animals 
than in TT animals.  The rabies antibody titres for all POMC genotypes increased steadily 
from day 0 to day 42 although it did not have any significant differences between the 
measurements on days 0, 21 and 42 for any of the CC, CT and TT animals. 
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6.0. CONCLUSION 
 
          The motive behind this research was to ascertain whether there is a correlation 
between the genotypes of both leptin and POMC and immune response by measuring the 
number and types of immune cells as well as antibody titres after introducing a rabies 
vaccine.  The outcome indicates that there is an interrelationship between leptin 
genotypes and immune response.  On day 0 there was significant variation with the leptin 
genotype in only two cell types but in four cell types on day 42.  Rabies antibody titres 
also showed significant differences among the leptin genotypes. 
          It should however be noted that some researchers have indicated that leptin’s effect 
is more pronounced in the control of body weight but not in inflammatory or 
hematopoietic processes (Agnello et al. 1998).  They also found that it is only at doses 
higher than those required to cause body weight loss in vivo that leptin functions as a pro-
inflammatory cytokine. 
          The effect of POMC on immune cells was not well pronounced.  POMC genotype 
appeared to have had a negative effect on the number of immune cell output.  There were 
four immune cell types that had variations among the POMC genotypes on day 0 and two 
cell types on day 42.  There was also no significant outcome in the rabies antibody titres 
with POMC genotype.  Adachi et al. (1999) observed that the POMC derived peptide α-
MSH down modulates the cytokines IL-1 β, TNF-α and lymphotactin.  It is possible that 
α-MSH could also have an effect on the stimulation of immune cells.  Blalock (1999) 
also supported the finding of Adachi et al. (1999) with his finding that α-MSH 
functionally acts as an IL-1 antagonist. 
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          Although there were significant differences in the specific immune cell output in 
relation to SNPs in both hormones, there was no consistent pattern observed with regards 
to allelic preference.  This was also true for the rabies antibody titres for leptin genotype.  
In previous studies, the T allele in leptin has been associated with carcass quality in beef 
and with milk yield in dairy cattle (Buchanan et al. 2002; 2003).  The T allele in POMC 
has also been linked with yield in beef cattle (Buchanan et al. 2005).  This was however 
not the situation in terms of immune response as neither the T or C allele seem to be 
distinctively exhibiting a clear expediency in immune response.  Hence, there is no allele 
advantage at either gene with leucocyte numbers.  Consequently, selection based on 
either the C or T allele should not negatively affect animal immune function. 
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6.1. Future Research 
 
          Based on the fact that animals used in this research were from different herds, there 
is the possibility of variation in diets fed to these animals.  Feed could be a potential 
confounding factor to the outcome of this research.  Dietary source of lipids and 
deficiencies or excessive use of trace minerals such as copper and zinc in animal rations 
could result in discrepancies in the immune functions of ruminants (Drouillard et al. 
2001; Minatel and Carfagnini 2000).  Graham (1991) also found that in cattle, selenium 
deficiency results in immune dysfunction causing changes in the normal 
immunoresponsiveness or control of inflammation. 
          In view of the aforementioned, an experimental model which combines the present 
immune data and genotypes with nutrition, could be designed for researching into the 
possible effect nutrition could have on immune response and hence on the outcome of 
this research. 
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APPENDIX A 
 
Effect of leptin genotypes on numbers of immune cell types on day 0 
 
Cell Type Genotype 
Comparison 
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% 
C.I 
P-
Value 
LogCD8gd (CD8 gamma 
delta cells) 
    0.620 
 CC-TT -0.007 -0.061 0.046 0.790 
 CT-TT 0.009 -0.039 0.057 0.715 
 CC-CT -0.016 -0.049 0.017 0.339 
LogCD4CD8Ratio (Ratio of 
CD4 to CD8) 
    0.874 
 CC-TT -0.010 -0.051 0.030 0.618 
 CT-TT -0.009 -0.045 0.027 0.629 
 CC-CT -0.001 -0.027 0.024 0.917 
LogCD5CD21 & B cells     0.552 
 CC-TT -0.006 -0.066 0.054 0.834 
 CT-TT 0.013 -0.040 0.067 0.625 
 CC-CT -0.020 -0.057 0.017 0.297 
LogCD4_25 (IL-2)     0.300 
 CC-TT -0.014 -0.057 0.029 0.523 
 CT-TT 0.007 -0.031 0.046 0.706 
 CC-CT -0.021 -0.048 0.005 0.117 
LogCD4CD25CD45-
LeucocyteCommonAntigen 
    0.928 
 CC-TT 0.009 -0.039 0.057 0.725 
 CT-TT 0.008 -0.035 0.051 0.706 
 CC-CT 0.000 -0.030 0.030 0.983 
LogCD4_26_45 (Activated 
CD4) 
    0.111 
 CC-TT -0.063 -0.123 -0.004 0.036 
 CT-TT -0.045 -0.098 0.008 0.095 
 CC-CT -0.018 -0.055 0.019 0.330 
LogCD8CD25CD45 -
(Activated CD8) 
    0.144 
 CC-TT -0.058 -0.117 -0.000 0.050 
 CT-TT -0.043 -0.095 -0.009 0.106 
 CC-CT -0.015 -0.052 0.021 0.401 
LogCD8CD26CD45 
(Activated CD8) 
    0.834 
 CC-TT 0.016 -0.048 0.080 0.629 
 CT-TT 0.018 -0.039 0.075 0.547 
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 CC-CT -0.002 -0.041 0.038 0.929 
LogCD8 (CD8-regular cells)     0.613 
 CC-TT -0.015 -0.066 0.036 0.574 
 CT-TT 0.001 -0.045 0.047 0.957 
 CC-CT -0.016 -0.048 0.016 0.326 
LogCD4 (CD4-regular cells)      0.471 
 CC-TT -0.024 -0.072 0.024 0.324 
 CT-TT -0.007 -0.050 0.036 0.738 
 CC-CT -0.017 -0.046 0.013 0.269 
LogW.C.1 cells     0.661 
 CC-TT -0.030 -0.097 0.037 0.380 
 CT-TT -0.017 -0.077 0.043 0.583 
 CC-CT -0.013 -0.055 0.029 0.535 
Log B cells     0.545 
 CC-TT -0.016 -0.068 0.037 0.560 
 CT-TT 0.003 -0.044 0.050 0.910 
 CC-CT -0.018 -0.051 0.014 0.272 
 
 
 
Effect of leptin genotype on numbers of immune cell types on day 42 
 
Cell Type Genotype 
Comparison 
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% 
C.I 
P-
Value 
LogCD8gd (CD8 gamma 
delta cells) 
    0.019 
 CC-TT 0.009 -0.052 0.069 0.780 
 CT-TT -0.039 -0.095 0.017 0.173 
 CC-CT 0.048 0.013 0.083 0.007 
LogCD4CD8Ratio (Ratio of 
CD4 to CD8) 
    0.183 
 CC-TT -0.026 -0.070 0.018 0.245 
 CT-TT -0.003 -0.043 0.037 0.884 
 CC-CT -0.023 -0.048 0.002 0.075 
LogCD5CD21 & B cells     0.963 
 CC-TT 0.009 -0.057 0.075 0.788 
 CT-TT 0.006 -0.055 0.067 0.846 
 CC-CT 0.003 -0.035 0.041 0.878 
LogCD4_25 (IL-2)     0.201 
 CC-TT -0.018 -0.065 0.028 0.440 
 CT-TT -0.034 -0.078 0.009 0.121 
 CC-CT 0.0159 -0.011 0.043 0.249 
LogCD4CD25CD45-     0.286 
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LeucocyteCommonAntigen 
 CC-TT -0.009 -0.063 0.044 0.730 
 CT-TT -0.029 -0.079 0.020 0.245 
 CC-CT 0.020 -0.011 0.051 0.206 
LogCD4_26_45 (Activated 
CD4) 
    0.071 
 CC-TT -0.016 -0.085 0.053 0.651 
 CT-TT -0.054 -0.118 0.010 0.098 
 CC-CT 0.038 -0.002 0.078 0.062 
LogCD8CD25CD45 -
(Activated CD8) 
    0.035 
 CC-TT -0.022 -0.087 0.043 0.499 
 CT-TT -0.061 -0.121 -0.000 0.048 
 CC-CT 0.038 0.001 0.076 0.046 
LogCD8CD26CD45 
(Activated CD8) 
    0.068 
 CC-TT 0.002 -0.069 0.072 0.961 
 CT-TT -0.042 -0.107 0.023 0.202 
 CC-CT 0.044 0.004 0.085 0.033 
LogCD8 (CD8-regular cells)     0.148 
 CC-TT -0.017 -0.072 0.038 0.549 
 CT-TT -0.040 -0.091 0.011 0.121 
 CC-CT 0.024 -0.008 0.055 0.147 
LogCD4 (CD4-regular cells)      0.180 
 CC-TT -0.043 -0.094 0.008 0.095 
 CT-TT -0.044 -0.091 0.003 0.067 
 CC-CT 0.001 -0.029 0.030 0.967 
Log W.C. 1 cells     0.050 
 CC-TT -0.096 -0.179 -0.014 0.023 
 CT-TT -0.054 -0.130 0.023 0.169 
 CC-CT -0.043 -0.090 0.005 0.079 
Log B cells     0.561 
 CC-TT -0.027 -0.083 0.029 0.342 
 CT-TT -0.028 -0.080 0.024 0.286 
 CC-CT 0.001 -0.031 0.033 0.949 
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APPENDIX B 
 
Rabies antibody titres for leptin 
 
Day Genotype 
Comparison 
Coefficient 
of Regression 
(β) 
Lower 
95%C.I 
Upper 
95%C.I 
P-value 
Logdiff0to21     0.133 
 CC-TT 0.137 -0.015 0.290 0.078 
 CT-TT 0.141 0.002 0.280 0.047 
 CC-CT -0.004 -0.098 0.091 0.940 
Logdiff0to42     0.090 
 CC-TT 0.188 0.009 0.367 0.039 
 CT-TT 0.179 0.014 0.345 0.034 
 CC-CT 0.009 -0.095 0.113 0.866 
Logdiff21to42     0.942 
 CC-TT 0.028 -0.158 0.214 0.770 
 CT-TT 0.030 -0.142 0.203 0.730 
 CC-CT -0.003 -0.110 0.105 0.961 
 
 
 
 
 
 
 
Rabies antibody titres for POMC 
 
Day Genotype 
Comparison 
Coefficient 
of Regression 
(β) 
Lower 
95%C.I 
Upper 
95%C.I 
P-value 
Logdiff0to21     0.386 
 CC-TT -0.092 -0.264 0.081 0.297 
 CT-TT -0.121 -0.294 0.053 0.173 
 CC-CT 0.029 -0.067 0.125 0.555 
Logdiff0to42     0.470 
 CC-TT 0.038 -0.157 0.233 0.703 
 CT-TT -0.030 -0.224 0.165 0.765 
 CC-CT 0.067 -0.040 0.175 0.219 
Logdiff21to42     0.624 
 CC-TT 0.093 -0.106 0.292 0.360 
 CT-TT 0.061 -0.137 0.260 0.545 
 CC-CT 0.032 -0.077 0.141 0.570 
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APPENDIX C 
 
Effect of POMC genotypes on numbers of immune cell types on day 0 
 
Cell Type Genotype 
Comparison 
Coefficient 
of 
Regression 
(β) 
Lower 
95% C.I 
Upper 
95% 
C.I 
P-
Value 
LogCD8gd (CD8 gamma 
delta cells) 
    0.291 
 CC-TT 0.000 -0.056 0.057 0.987 
 CT-TT 0.025 -0.030 0.081 0.372 
 CC-CT -0.025 -0.058 0.008 0.137 
Ratio of CD4 to CD8     0.065 
 CC-TT -0.020 -0.062 0.023 0.364 
 CT-TT -0.042 -0.084 0.000 0.051 
 CC-CT 0.022 -0.002 0.047 0.077 
LogCD5CD21 & B cells     0.176 
 CC-TT 0.058 -0.006 0.123 0.077 
 CT-TT 0.037 -0.027 0.101 0.256 
 CC-CT 0.021 -0.016 0.059 0.266 
LogCD4_25 (IL-2)      0.592 
 CC-TT 0.016 -0.030 0.062 0.490 
 CT-TT 0.023 -0.022 0.069 0.320 
 CC-CT -0.007 -0.034 0.020 0.616 
LogCD4CD25CD45-
LeucocyteCommonAntigen 
    0.236 
 CC-TT 0.038 -0.014 0.090 0.152 
 CT-TT 0.018 -0.034 0.069 0.498 
 CC-CT 0.020 -0.010 0.051 0.187 
LogCD4_26_45 (Activated 
CD4) 
    0.006 
 CC-TT 0.001 -0.063 0.065 0.966 
 CT-TT 0.059 -0.004 0.122 0.065 
 CC-CT -0.058 -0.095 -0.021 0.002 
LogCD8CD25CD45 
(Activated CD8) 
    0.012 
 CC-TT 0.008 -0.055 0.070 0.812 
 CT-TT 0.058 -0.003 0.120 0.064 
 CC-CT -0.051 -0.087 -0.014 0.006 
LogCD8CD26CD45 
(Activated CD8) 
    0.210 
 CC-TT 0.001 -0.068 0.070 0.983 
 CT-TT 0.034 -0.033 0.102 0.318 
 CC-CT -0.034 -0.073 0.006 0.095 
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LogCD8 (CD8-regular cells)     0.064 
 CC-TT 0.015 -0.039 0.070 0.580 
 CT-TT 0.048 -0.006 0.101 0.083 
 CC-CT -0.032 -0.064 -0.001 0.046 
LogCD4 (CD4-regular cells)      0.848 
 CC-TT -0.005 -0.056 0.046 0.854 
 CT-TT 0.004 -0.047 0.054 0.880 
 CC-CT -0.009 -0.039 0.021 0.566 
LogW.C.1 cells     0.709 
 CC-TT -0.030 -0.102 0.043 0.418 
 CT-TT -0.021 -0.092 0.051 0.566 
 CC-CT -0.090 -0.051 0.033 0.677 
Log B cells     0.101 
 CC-TT 0.017 -0.053 0.073 0.553 
 CT-TT -0.019 -0.074 0.037 0.509 
 CC-CT 0.035 0.003 0.068 0.032 
 
 
 
 
 
Effect of POMC genotypes on numbers of immune cell types on day 42 
 
Cell Type Genotype 
Comparison 
Coefficient 
of 
Regression 
(β) 
Lower 
95% 
C.I 
Upper 
95% 
C.I 
P-Value 
LogCD8gd (CD8 gamma 
delta cells) 
    0.746 
 CC-TT -0.010 -0.076 0.055 0.759 
 CT-TT 0.004 -0.061 0.068 0.907 
 CC-CT -0.014 -0.050 0.022 0.447 
LogCD4CD8Ratio (Ratio of 
CD4 to CD8) 
    0.091 
 CC-TT -0.030 -0.077 0.017 0.206 
 CT-TT -0.047 -0.093 -0.002 0.043 
 CC-CT 0.017 -0.008 0.043 0.186 
LogCD5CD21 & B cells     0.606 
 CC-TT 0.031 -0.040 0.102 0.396 
 CT-TT 0.036 -0.034 0.106 0.317 
 CC-CT -0.005 -0.045 0.035 0.804 
LogCD4_25 (IL-2)     0.860 
 CC-TT -0.013 -0.063 0.038 0.625 
 CT-TT -0.007 -0.057 0.043 0.783 
 CC-CT -0.006 -0.034 0.023 0.696 
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LogCD4CD25CD45-
LeucocyteCommonAntigen 
    0.809 
 CC-TT 0.011 -0.048 0.070 0.711 
 CT-TT 0.001 -0.057 0.059 0.981 
 CC-CT 0.010 -0.022 0.043 0.534 
LogCD4_26_45 (Activated 
CD4) 
    0.190 
 CC-TT -0.020 -0.096 0.055 0.599 
 CT-TT 0.019 -0.056 0.093 0.619 
 CC-CT -0.039 -0.081 0.003 0.0686 
LogCD8CD25CD45 -
(Activated CD8) 
    0.217 
 CC-TT -0.005 -0.075 0.066 0.894 
 CT-TT 0.029 -0.040 0.099 0.408 
 CC-CT -0.034 -0.073 0.005 0.090 
LogCD8CD26CD45-
(Activated CD8) 
    0.128 
 CC-TT -0.009 -0.085 0.067 0.812 
 CT-TT 0.034 -0.041 0.109 0.376 
 CC-CT -0.043 -0.085 -0.001 0.047 
LogCD8 (CD8-regular cells)     0.672 
 CC-TT 0.011 -0.049 0.071 0.712 
 CT-TT 0.022 -0.037 0.082 0.455 
 CC-CT -0.011 -0.045 0.022 0.508 
LogCD4 (CD4-regular cells)      0.673 
 CC-TT -0.018 -0.073 0.037 0.518 
 CT-TT -0.024 -0.078 0.030 0.382 
 CC-CT 0.006 -0.024 0.036 0.699 
LogW.C.1 cells     0.727 
 CC-TT -0.017 -0.107 0.072 0.701 
 CT-TT -0.031 -0.119 0.057 0.484 
 CC-CT 0.014 -0.036 0.063 0.583 
Log B cells     0.171 
 CC-TT 0.008 -0.052 0.067 0.802 
 CT-TT -0.024 -0.083 0.035 0.430 
 CC-CT 0.031 -0.002 0.065 0.064 
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APPENDIX D 
 
Descriptive statistics 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8gd (CD8 gamma delta 
cells) 
     556 
Leptin CC 0.212 0.114 0.189 0.107 149 
 CT 0.221 0.115 0.202 0.149 345 
 TT 0.205 0.119 0.177 0.131 62 
POMC      519 
 CC 0.208 0.104 0.189 0.136 288 
 CT 0.221 0.113 0.199 0.141 188 
 TT 0.199 0.080 0.199 0.100 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4CD8Ratio (Ratio of 
CD4 to CD8) 
     556 
Leptin CC 1.181 0.385 1.128 0.440 149 
 CT 1.192 0.392 1.132 0.528 345 
 TT 1.252 0.392 1.188 0.522 62 
POMC      519 
 CC 1.227 0.385 1.176 0.463 288 
 CT 1.177 0.393 1.126 0.532 188 
 TT 1.214 0.387 1.150 0.504 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD5CD21 & B cells      556 
Leptin CC 0.369 0.209 0.313 0.276 149 
 CT 0.388 0.209 0.345 0.261 345 
 TT 0.410 0.249 0.370 0.362 62 
POMC      519 
 CC 0.407 0.230 0.354 0.314 288 
 CT 0.368 0.187 0.322 0.243 188 
 TT 0.322 0.164 0.285 0.196 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4_25 (IL-2)      556 
Leptin CC 0.164 0.071 0.155 0.090 149 
 CT 0.176 0.081 0.168 0.100 345 
 TT 0.176 0.080 0.177 0.108 62 
 
 
POMC 
     
 
 
 
 
519 
 CC 0.177 0.081 0.167 0.109 288 
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 CT 0.171 0.077 0.155 0.094 188 
 TT 0.155 0.066 0.140 0.082 43 
CD4CD25CD45-
LeucocyteCommonAntigen 
     556 
Leptin CC 1.162 0.597 1.011 0.648 149 
 CT 1.183 0.805 1.071 0.552 345 
 TT 1.149 0.591 1.081 0.627 62 
POMC      519 
 CC 1.271 0.902 1.113 0.671 288 
 CT 1.082 0.482 1.012 0.522 188 
 TT 1.036 0.432 1.011 0.442 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4_26_45 (Activated 
CD4) 
     556 
Leptin CC 0.054 0.037 0.043 0.042 149 
 CT 0.061 0.040 0.050 0.054 345 
 TT 0.057 0.035 0.050 0.036 62 
POMC      519 
 CC 0.058 0.041 0.046 0.047 288 
 CT 0.060 0.038 0.049 0.047 188 
 TT 0.052 0.028 0.048 0.046 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8CD25CD45 (Activated 
CD8) 
     556 
Leptin CC 0.060 0.046 0.047 0.039 149 
 CT 0.239 3.238 0.054 0.050 345 
 TT 0.059 0.039 0.051 0.041 62 
POMC      519 
 CC 0.272 3.544 0.049 0.044 288 
 CT 0.064 0.040 0.053 0.050 188 
 TT 0.055 0.029 0.046 0.038 43 
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DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8CD26CD45 (Activated 
CD8) 
     556 
Leptin CC 0.068 0.044 0.055 0.054 149 
 CT 0.073 0.053 0.060 0.054 345 
 TT 0.064 0.053 0.047 0.037 62 
POMC      519 
 CC 0.066 0.045 0.052 0.053 288 
 CT 0.077 0.059 0.060 0.054 188 
 TT 0.074 0.051 0.057 0.069 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8 (CD8-regular cells)      556 
Leptin CC 0.674 0.325 0.632 0.429 149 
 CT 0.702 0.332 0.648 0.454 345 
 TT 0.688 0.405 0.616 0.457 62 
POMC      519 
 CC 0.677 0.324 0.642 0.490 288 
 CT 0.698 0.312 0.628 0.423 188 
 TT 0.609 0.235 0.547 0.303 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4 (CD4-regular cells)      556 
Leptin CC 0.748 0.331 0.690 0.461 149 
 CT 0.787 0.354 0.733 0.513 345 
 TT 0.789 0.381 0.716 0.510 62 
POMC      519 
 CC 0.786 0.364 0.738 0.515 288 
 CT 0.773 0.340 0.700 0.515 188 
 TT 0.706 0.306 0.638 0.400 43 
 
DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
W.C. 1 cells      556 
Leptin CC 0.695 0.404 0.657 0.506 149 
 CT 0.765 1.238 0.623 0.462 345 
 TT 0.683 0.392 0.591 0.455 62 
POMC      519 
 CC 0.805 1.360 0.653 0.521 288 
 CT 0.663 0.317 0.614 0.435 188 
 TT 0.692 0.373 0.623 0.472 43 
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DAY 0 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
B cells      556 
Leptin CC 1.807 0.919 1.569 1.176 149 
 CT 1.793 0.797 1.636 0.949 345 
 TT 1.768 0.832 1.740 1.178 62 
POMC      519 
 CC 1.909 0.918 1.718 1.215 288 
 CT 1.664 0.699 1.595 0.916 188 
 TT 1.605 0.589 1.493 0.778 43 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8gd (CD8 gamma delta 
cells) 
     443 
Leptin CC 1.556 0.733 1.416 1.028 129 
 CT 1.377 0.656 1.253 0.766 272 
 TT 1.497 0.678 1.406 1.057 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 1.426 0.692 1.327 0.899 227 
 CT 1.476 0.700 1.334 0.912 156 
 TT 1.456 0.565 1.352 0.608 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4CD8Ratio (Ratio of 
CD4 to CD8) 
     443 
Leptin CC 1.144 0.382 1.110 0.427 129 
 CT 1.201 0.380 1.160 0.546 272 
 TT 1.279 0.367 1.215 0.545 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 1.219 0.396 1.154 0.551 227 
 CT 1.169 0.367 1.151 0.527 156 
 TT 1.171 0.331 1.161 0.459 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD5CD21 & B cells      443 
Leptin CC 0.452 0.242 0.390 0.307 129 
 CT 0.459 0.228 0.421 0.314 272 
 TT 0.479 0.236 0.451 0.226 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.487 0.243 0.435 0.342 227 
 CT 0.451 0.213 0.414 0.257 156 
 TT 0.388 0.227 0.348 0.226 32 
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DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4_25 (IL-2)      443 
Leptin CC 0.244 0.096 0.237 0.139 129 
 CT 0.240 0.095 0.233 0.126 272 
 TT 0.270 0.096 0.271 0.139 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.250 0.097 0.238 0.132 227 
 CT 0.240 0.090 0.240 0.119 156 
 TT 0.219 0.098 0.223 0.141 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4CD25CD45-
LeucocyteCommonAntigen 
     443 
Leptin CC 1.333 0.473 1.326 0.688 129 
 CT 1.315 0.479 1.288 0.621 272 
 TT 1.405 0.459 1.342 0.621 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 1.390 0.480 1.380 0.606 227 
 CT 1.273 0.435 1.246 0.577 156 
 TT 1.229 0.525 1.154 0.680 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4_26_45 (Activated 
CD4) 
     443 
Leptin CC 0.151 0.082 0.140 0.125 129 
 CT 0.143 0.077 0.134 0.110 272 
 TT 0.156 0.092 0.136 0.096 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.139 0.080 0.127 0.113 227 
 CT 0.154 0.074 0.148 0.098 156 
 TT 0.139 0.084 0.129 0.135 32 
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DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8CD25CD45 (Activated 
CD8) 
     443 
Leptin CC 0.149 0.079 0.138 0.103 129 
 CT 0.136 0.072 0.132 0.094 272 
 TT 0.152 0.096 0.129 0.098 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.132 0.069 0.125 0.087 227 
 CT 0.152 0.077 0.147 0.094 156 
 TT 0.134 0.087 0.123 0.149 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8CD26CD45 (Activated 
CD8) 
     443 
Leptin CC 0.134 0.081 0.118 0.106 129 
 CT 0.123 0.077 0.112 0.094 272 
 TT 0.143 0.095 0.119 0.085 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.128 0.083 0.107 0.096 227 
 CT 0.127 0.069 0.120 0.089 156 
 TT 0.109 0.081 0.096 0.126 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD8 (CD8-regular cells)      443 
Leptin CC 0.817 0.352 0.774 0.468 129 
 CT 0.795 0.340 0.754 0.417 272 
 TT 0.877 0.432 0.809 0.484 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.806 0.361 0.786 0.461 227 
 CT 0.802 0.316 0.745 0.378 156 
 TT 0.761 0.266 0.721 0.317 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
CD4 (CD4-regular cells)      443 
Leptin CC 0.871 0.355 0.819 0.445 129 
 CT 0.898 0.370 0.862 0.460 272 
 TT 1.043 0.382 1.051 0.409 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.912 0.385 0.858 0.477 227 
 CT 0.889 0.346 0.872 0.444 156 
 TT 0.884 0.364 0.843 0.503 32 
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DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
W.C. 1 cells      443 
Leptin CC 0.613 0.395 0.503 0.480 129 
 CT 0.675 0.417 0.570 0.510 272 
 TT 0.754 0.357 0.736 0.405 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 0.676 0.401 0.579 0.541 227 
 CT 0.621 0.367 0.562 0.474 156 
 TT 0.679 0.471 0.520 0.518 32 
 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
B cells      443 
Leptin CC 1.814 0.756 1.702 1.078 129 
 CT 1.818 0.717 1.724 0.947 272 
 TT 2.131 0.876 1.892 1.109 42 
DAY 42 - OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER 
POMC      415 
 CC 1.946 0.771 1.830 1.039 227 
 CT 1.752 0.674 1.695 0.982 156 
 TT 1.809 0.823 1.633 1.014 32 
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RABIES ANTIBODY TITRES 
 
OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER
Day 0 Titre      586 
Leptin CC 5.210 1.378 5.000 0.000 163 
 CT 5.390 3.034 5.000 0.000 358 
 TT 9.230 25.850 5.000 0.000 65 
POMC      550 
 CC 6.100 11.836 5.000 0.000 316 
 CT 5.430 3.855 5.000 0.000 193 
 TT 5.200 1.249 5.000 0.000 41 
 
OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER
Day 21 Titre      579 
Leptin CC 327.870 532.583 170.000 215.000 163 
 CT 325.240 522.065 180.000 264.000 353 
 TT 271.860 357.878 210.000 214.000 63 
POMC      545 
 CC 324.770 481.166 200.000 264.000 315 
 CT 296.830 455.584 125.000 214.000 190 
 TT 434.180 939.647 255.000 250.000 40 
 
OUTCOME GENOTYPE MEAN S.D MEDIAN IQR NUMBER
Day 42 Titre      533 
Leptin CC 7349.880 20205.636 1800.000 5600.000 157 
 CT 6675.000 17875.214 1600.000 4900.000 325 
 TT 6753.240 22322.986 1600.000 5700.000 51 
POMC      501 
 CC 9262.42 25131.309 1800.000 5200.000 283 
 CT 4408.090 6988.967 1600.000 5450.000 181 
 TT 4126.080 6594.076 1600.000 4150.000 37 
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APPENDIX E  
 
Least Square Means 
 
Leptin day 0     
 
Cell Type GENOTYPE LSMEAN L.C.I U.C.I 
CD8gd (CD8 gamma delta cells)     
 CC 0.152 0.132 0.176 
 CT 0.158 0.138 0.181 
 TT 0.155 0.132 0.182 
CD4CD8Ratio (Ratio of CD4 to CD8)     
 CC 1.151 1.051 1.261 
 CT 1.155 1.063 1.255 
 TT 1.179 1.058 1.313 
CD5CD21 & B cells     
 CC 0.275 0.233 0.323 
 CT 0.287 0.247 0.335 
 TT 0.279 0.232 0.335 
CD4_25 (IL-2)     
 CC 0.124 0.110 0.140 
 CT 0.130 0.117 0.146 
 TT 0.128 0.112 0.146 
CD4CD25CD45 (LeucocyteCommonAntigen) 
    
 CC 0.886 0.774 1.014 
 CT 0.885 0.779 1.006 
 TT 0.868 0.746 1.010 
CD4_26_45 (Activated CD4)     
 CC 0.037 0.029 0.045 
 CT 0.038 0.031 0.047 
 TT 0.042 0.034 0.053 
CD8CD25CD45 (Activated CD8)     
 CC 0.040 0.033 0.049 
 CT 0.042 0.034 0.051 
 TT 0.046 0.037 0.057 
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CD8CD26CD45 (Activated CD8) 
 CC 0.046 0.038 0.056 
 CT 0.046 0.038 0.055 
 TT 0.044 0.036 0.055 
CD8 (CD8-regular cells)     
 CC 0.498 0.437 0.567 
 CT 0.516 0.458 0.582 
 TT 0.515 0.444 0.597 
CD4 (CD4-regular cells)     
 CC 0.573 0.501 0.656 
 CT 0.596 0.524 0.677 
 TT 0.606 0.521 0.705 
W.C. 1 cells     
 CC 0.528 0.453 0.616 
 CT 0.544 0.473 0.627 
 TT 0.566 0.472 0.678 
B cells     
 CC 1.339 1.192 1.505 
 CT 1.397 1.258 1.553 
 TT 1.388 1.209 1.594 
 
 
POMC day 0     
 
Cell Type     
CD8gd (CD8 gamma delta cells)     
 CC 0.151 0.132 0.173 
 CT 0.160 0.140 0.184 
 TT 0.151 0.128 0.180 
CD4CD8Ratio (Ratio of CD4 to CD8)     
 CC 1.179 1.085 1.280 
 CT 1.120 1.028 1.220 
 TT 1.233 1.099 1.383 
CD5CD21 & B cells     
 CC 0.293 0.252 0.341 
 CT 0.279 0.239 0.325 
 TT 0.256 0.211 0.311 
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CD4_25 (IL-2)     
 CC 0.128 0.114 0.143 
 CT 0.130 0.116 0.146 
 TT 0.123 0.107 0.142 
CD4CD25CD45-LeucocyteCommonAntigen 
    
 CC 0.907 0.796 1.034 
 CT 0.866 0.758 0.990 
 TT 0.831 0.706 0.979 
CD4_26_45 (Activated CD4)     
 CC 0.036 0.029 0.045 
 CT 0.041 0.033 0.051 
 TT 0.036 0.028 0.046 
CD8CD25CD45 (Activated CD8)     
 CC 0.040 0.033 0.048 
 CT 0.045 0.037 0.055 
 TT 0.039 0.031 0.049 
CD8CD26CD45 (Activated CD8) 
    
 CC 0.044 0.037 0.053 
 CT 0.048 0.039 0.058 
 TT 0.044 0.035 0.055 
CD8 (CD8-regular cells)     
 CC 0.495 0.440 0.558 
 CT 0.533 0.472 0.602 
 TT 0.478 0.409 0.559 
CD4 (CD4-regular cells)     
 CC 0.584 0.513 0.665 
 CT 0.596 0.522 0.680 
 TT 0.590 0.502 0.694 
W.C. 1 cells     
 CC 0.534 0.461 0.619 
 CT 0.545 0.468 0.634 
 TT 0.572 0.468 0.699 
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B cells 
 CC 1.436 1.295 1.592 
 CT 1.323 1.189 1.473 
 TT 1.381 1.192 1.600 
 
Leptin day 42     
 
Cell Type GENOTYPE  LSMEAN  L.C.I U.C.I 
CD8gd (CD8 gamma delta cells)-     
 CC 0.993 0.837 1.177 
 CT 0.889 0.754 1.050 
 TT 0.973 0.798 1.187 
CD4CD8Ratio (Ratio of CD4 to CD8)     
 CC 1.130 0.987 1.294 
 CT 1.192 1.044 1.360 
 TT 1.200 1.029 1.400 
CD5CD21 & Bcells     
 CC 0.296 0.244 0.360 
 CT 0.294 0.244 0.355 
 TT 0.290 0.232 0.363 
CD4_25 (IL-2)     
 CC 0.162 0.138 0.190 
 CT 0.156 0.133 0.183 
 TT 0.169 0.141 0.202 
CD4CD25CD45-LeucocyteCommonAntigen 
    
 CC 0.978 0.848 1.128 
 CT 0.934 0.814 1.072 
 TT 1.000 0.844 1.184 
CD4_26_45 (Activated CD4)     
 CC 0.098 0.077 0.125 
 CT 0.090 0.071 0.114 
 TT 0.102 0.078 0.133 
CD8CD25CD45 (Activated CD8)     
 CC 0.092 0.072 0.116 
 CT 0.084 0.066 0.106 
 TT 0.096 0.074 0.125 
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CD8CD26CD45 (Activated CD8) 
    
 CC 0.085 0.064 0.114 
 CT 0.077 0.058 0.102 
 TT 0.085 0.062 0.116 
CD8 (CD8-regular cells)     
 CC 0.513 0.438 0.600 
 CT 0.486 0.417 0.566 
 TT 0.533 0.444 0.640 
CD4 (CD4-regular cells)     
 CC 0.581 0.498 0.679 
 CT 0.581 0.499 0.675 
 TT 0.642 0.538 0.766 
W.C. 1 cells     
 CC 0.374 0.288 0.485 
 CT 0.412 0.319 0.532 
 TT 0.466 0.347 0.626 
B cells     
 CC 1.205 1.038 1.398 
 CT 1.202 1.041 1.388 
 TT 1.282 1.075 1.529 
POMC day 42     
 
Cell Type     
 
CD8gd (CD8 gamma delta cells)     
 CC 0.865 0.725 1.032 
 CT 0.894 0.746 1.071 
 TT 0.886 0.716 1.096 
CD4CD8Ratio (Ratio of CD4 to CD8)     
 CC 1.136 0.986 1.310 
 CT 1.091 0.945 1.261 
 TT 1.217 1.033 1.435 
CD5CD21 & B cells     
 CC 0.288 0.236 0.351 
 CT 0.292 0.238 0.357 
 TT 0.269 0.212 0.340 
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CD4_25 (IL-2) 
 CC 0.156 0.132 0.185 
 CT 0.158 0.133 0.187 
 TT 0.160 0.133 0.194 
CD4CD25CD45-LeucocyteCommonAntigen 
    
 CC 0.960 0.829 1.112 
 CT 0.938 0.807 1.090 
 TT 0.936 0.780 1.123 
CD4_26_45 (Activated CD4)     
 CC 0.089 0.069 0.115 
 CT 0.098 0.075 0.127 
 TT 0.093 0.070 0.125 
CD8CD25CD45 (Activated CD8)     
 CC 0.085 0.066 0.109 
 CT 0.092 0.071 0.118 
 TT 0.086 0.065 0.113 
CD8CD26CD45 (Activated CD8) 
    
 CC 0.079 0.058 0.107 
 CT 0.087 0.064 0.118 
 TT 0.081 0.058 0.112 
CD8 (CD8-regular cells)     
 CC 0.494 0.420 0.581 
 CT 0.507 0.429 0.599 
 TT 0.481 0.396 0.585 
CD4 (CD4-regular cells)     
 CC 0.566 0.482 0.666 
 CT 0.559 0.474 0.659 
 TT 0.590 0.489 0.713 
W.C. 1 cells     
 CC 0.409 0.311 0.539 
 CT 0.396 0.300 0.524 
 TT 0.426 0.310 0.585 
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B cells 
 CC 1.216 1.045 1.414 
 CT 1.131 0.969 1.320 
 TT 1.194 0.991 1.440 
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Least Square Means for Rabies Antibody Titres 
 
     
 
Leptin     
diff0to21a GENOTYPE LSMEAN L.C.I U.C.I 
 CC 27.265 21.372 34.783 
 CT 27.498 22.431 33.710 
 TT 19.879 14.186 27.857 
diff21to42a     
 CC 14.041 9.591 20.555 
 CT 14.129 9.942 20.079 
 TT 13.173 8.066 21.516 
diff0to42a     
 CC 381.593 272.966 533.446 
 CT 373.766 276.198 505.800 
 TT 247.286 158.319 386.249 
 
 
POMC     
diff0to21a     
 CC 26.724 21.502 33.213 
 CT 25.009 19.690 31.766 
 TT 33.007 22.025 49.462 
diff21to42a     
 CC 14.545 10.184 20.771 
 CT 13.524 9.334 19.595 
 TT 11.749 6.914 19.966 
diff0to42a     
 CC 383.001 282.283 519.656 
 CT 327.944 237.820 452.222 
 TT 351.075 215.246 572.617 
 
 
Legend 
 
L.C.I - Lower Confidence Interval 
U.C.I - Upper Confidence Interval 
a - diff refers to the difference in rabies antibody titres between the days in question 
Unit of LSMEAN = x106 cells /ml 
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APPENDIX F 
 
List of Animal Breeds with Genotypes 
 
VIAL No. SAMPLE/LAB No. LEPTIN  POMC  BREED SEX 
6001 221 CC CC Continental  Female 
6002 222 CT TT Continental Female 
6003 223 CT CT Continental Female 
6004 224 CT CC Continental Female 
6005 225 CC CC Continental Female 
6006 226 CT CC Continental Female 
6007 227 CT CC Continental Female 
6008 228 CC CC Continental Female 
6009 229 TT TT Continental Female 
6081 231 CC CC Continental Female 
6082 232 CT CC Continental Female 
6083 233 CT CT Continental Female 
6084 234 CT CC Continental Female 
6085 235 CT CC Continental Female 
6086 236 CC CC Continental Female 
6087 237 CC CC Continental Female 
6088 238 CC CC Continental Female 
6089 239 CT CC Continental Female 
6090 240 CC CC Continental Female 
6091 241 CC CT Continental Female 
6092 242 CC CC Continental Female 
6093 243 CC CT Continental Female 
6094 244 CC CT Continental Female 
6095 255 CT CC Continental Female 
6072 257 CC CT Unknown Female 
6074 259 CT TT Unknown Female 
6075 260 CT CT Unknown Female 
6077 262 CT CT Unknown Female 
6078 263 CC TT Unknown Female 
6080 265 CT CC Unknown Female 
6213 268 CT CC Unknown Female 
6215 270 CC CT Unknown Female 
6216 271 CT CT Unknown Female 
6218 273 CT CT Unknown Female 
6220 275 CT CC Unknown Female 
6612 277 CT CC Unknown Female 
6621 282 CC CC Continental Female 
6622 283 CC X Continental Female 
6623 284 CT CC Continental Female 
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6625 286 CT X Continental Female 
6626 287 CT X Continental Female 
6627 288 CC CT Continental Female 
6628 289 CT X Continental Female 
6630 291 CC X Continental Female 
6631 292 CC CC Continental Female 
6632 293 CT X Continental Female 
6633 294 CT X Continental Female 
6634 295 CT CC Continental Female 
6636 297 CT X Continental Female 
6637 298 TT CC Continental Female 
6638 299 CT CC Continental Female 
6639 300 CT X Continental Female 
6640 301 TT X Continental Female 
6641 302 CC CC Continental Female 
6643 304 CC CT Continental Female 
6191 305 CT CT Continental Female 
6192 306 CC CC Continental Female 
6193 307 CT X Continental Female 
6194 308 CT CT Continental Female 
6195 309 CT CT Continental Female 
6196 310 CC CT Continental Female 
6197 311 CT TT Continental Female 
6198 312 CT X Continental Female 
6199 313 CC CC Continental Female 
6200 314 CT X Continental Female 
6491 315 CT CC Continental Female 
6492 316 CT X Continental Female 
6493 317 CC CC Continental Female 
6494 318 CT CT Continental Female 
6495 319 CT X Continental Female 
6496 320 CC X Continental Female 
6497 321 CT CC Continental Female 
6498 322 CT CC Continental Female 
6500 324 CC CT Continental Female 
6501 325 CT CT Continental Female 
6502 326 CT CT Continental Female 
6503 327 CC CC Continental Female 
6614 328 CT X Unknown Female 
6616 330 CT CT Unknown Female 
6618 332 CT TT Unknown Female 
6619 333 CT TT Unknown Female 
6620 334 CT CC Unknown Female 
6644 335 CT CC Continental Female 
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6646 337 CC CT Continental Female 
6647 338 CT CT Continental Female 
6648 339 CT CC Continental Female 
6649 340 TT CC Continental Female 
6951 342 CT CT Continental Female 
6953 344 TT CT Continental Female 
6954 345 TT CC Continental Female 
6955 346 CT TT Unknown Female 
6957 348 CC TT Unknown Female 
6504 352 CC CT Continental Female 
6505 353 CC CC Continental Female 
6506 354 CC CC Continental Female 
6507 355 CT CC Continental Female 
6508 356 CT CC Continental Female 
6509 357 CT CC Continental Female 
6510 358 CT CC Continental Female 
6869 359 CC TT Continental Female 
6861 360 CT CC Continental Female 
6862 361 CT CC Continental Female 
6863 362 CT X Continental Female 
6864 363 TT CC Continental Female 
6865 364 CC CT Continental Female 
6866 365 CT CT Continental Female 
6867 366 CT CC Continental Female 
6868 367 CT CT Continental Female 
6870 368 CC CC Continental Female 
6871 369 CT CT Continental Female 
6872 370 CC CT Continental Female 
6873 371 CC CC Continental Female 
6874 372 CT CC Continental Female 
6875 373 CT CC Continental Female 
6877 375 CT CC Continental Female 
6878 376 CT CC Continental Female 
6879 377 CT CT Continental Female 
6880 378 CC CC Continental Female 
6881 379 CT CC Continental Female 
6882 380 CC CC Continental Female 
6883 381 CC CC Continental Female 
6884 382 TT CC Continental Female 
6885 383 CC TT Continental Female 
6891 384 CT CC Continental Female 
6892 385 CT CC Continental Female 
6893 386 CT X Continental Female 
6894 387 CT TT Continental Female 
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6895 388 CT TT Continental Female 
6896 389 TT CC Continental Female 
6897 390 CT CC Continental Female 
6898 391 TT CT Continental Female 
6899 392 CC CT Continental Female 
6900 393 CT CT Continental Female 
6901 394 CT CT Continental Female 
6902 395 CC CC Continental Female 
6903 396 CT CC Continental Female 
6904 397 TT CC Continental Female 
6905 398 CC CT Continental Female 
6906 399 TT CC Continental Female 
6907 400 CT TT Continental Female 
6908 401 TT CT Continental Female 
6909 402 TT CC Continental Female 
6910 403 CT X Continental Female 
6301 404 CT CT British Female 
6302 405 TT CC British Female 
6304 407 TT CC British Female 
6305 408 CT CC British Female 
6306 409 CC CC British Female 
6307 410 CT CC British Female 
6330 411 CT CT British Female 
6309 412 CT CT British Female 
6310 413 TT CT British Female 
6311 414 CT CC British Female 
6312 415 CC CC British Female 
6313 416 TT CC British Female 
6314 417 CC CC British Female 
6316 419 CT CC British Female 
6317 420 TT CC British Female 
6318 421 TT X British Female 
6319 422 CC CC British Female 
6321 424 CC CC British Female 
6322 425 CT CT British Female 
6323 426 CT CT British Female 
6324 427 TT TT British Female 
6326 429 TT CT British Female 
6328 431 CT CC British Female 
6329 432 TT CC British Female 
6721 433 CT CT Continental Female 
6722 434 TT TT Continental Female 
6723 435 CC CT Continental Female 
6724 436 CT CT Continental Female 
 104
6725 437 CC CT Continental Female 
6727 439 CT CC Continental Female 
6728 440 CC CT Continental Female 
6729 441 CC CT Continental Female 
6732 444 CT CT Continental Female 
6733 445 CC CT Continental Female 
6734 446 TT TT Continental Female 
6735 447 CT CT Continental Female 
6736 448 CT X Continental Female 
6737 449 CT CT Continental Female 
6739 451 CT CT Continental Female 
6740 452 CC TT Continental Female 
6771 453 TT CT Continental Female 
6772 454 CC CC Continental Female 
6773 455 CC CT Continental Female 
6775 457 CT CT Continental Female 
6776 458 CT CT Continental Female 
6777 459 CT X Continental Female 
6778 460 CT CC Continental Female 
6780 462 CT CC Continental Female 
6781 463 CT CC Continental Female 
6782 464 CT CC Continental Female 
6783 465 CT CC Continental Female 
6784 466 CT CC Continental Female 
6801 468 TT CC Continental Female 
6802 469 CT CT Continental Female 
6803 470 CT CT Continental Female 
6804 471 CT CT Continental Female 
6805 472 CT CC Continental Female 
6806 473 CC CT Continental Female 
6807 474 CT CT Continental Female 
6808 475 CT CC Continental Female 
6809 476 CT CC Continental Female 
6810 477 CC CC Continental Female 
6811 478 CT CT Continental Female 
6812 479 CC TT Continental Female 
6813 480 CT CT Continental Female 
6814 481 CT CC Continental Female 
6815 482 CT CT Continental Female 
6816 483 CT CC Continental Female 
6817 484 CC CT Continental Female 
6818 485 CT CC Continental Female 
6819 486 CT CC Continental Female 
6820 487 CT CC Continental Female 
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6821 488 CC TT Continental Female 
6822 489 CT TT Continental Female 
6391 490 CT CT Continental Female 
6394 493 CT CT Continental Female 
6395 494 CT CT Continental Female 
6396 495 CT CT Continental Female 
6397 496 CT CT Continental Female 
6398 497 CT CT Continental Female 
6399 498 CT CT Continental Female 
6400 499 CT X Continental Female 
6411 500 CC CT British Female 
6416 501 CT CT British Female 
6417 502 CT CT British Female 
6419 504 CT CC British Female 
6786 506 CC TT Continental Female 
6787 507 CT CT Continental Female 
6788 508 CC TT Continental Female 
6790 509 CT CT Continental Female 
6791 510 CC CC Continental Female 
6792 511 CC CC Continental Female 
6795 514 CC CT Continental Female 
6796 515 CT X Continental Female 
6921 517 CT CC Continental Female 
6922 518 TT CC Continental Female 
6923 519 TT CT Continental Female 
6924 520 CC CT Continental Female 
6925 521 CC CC Continental Female 
6401 522 CT CC British Female 
6403 523 CT CC British Female 
6404 524 CT CC British Female 
6405 525 TT CC British Female 
6407 527 CT CT British Female 
6408 528 CC X British Female 
6412 531 CT X British Female 
6413 532 CT X British Female 
6414 533 CT X British Female 
6415 534 CT X British Female 
6421 535 CT X British Female 
6424 538 CT CC British Female 
6831 539 CC CC Cross Female 
6832 540 CT CC Cross Female 
6833 541 CT TT Cross Female 
6834 542 CT TT Cross Female 
6835 543 TT CT Cross Female 
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6836 544 CT CC Cross Female 
6837 545 CC CT Cross Female 
6838 546 CC CC Cross Female 
6839 547 CT CC Cross Female 
6841 549 CT CT Cross Female 
6842 550 CT CT Cross Female 
6843 551 CT CC Cross Female 
6844 552 CT CC Cross Female 
6845 553 CT CC Cross Female 
6846 554 CT CC Cross Female 
6847 555 CT CC Cross Female 
6848 556 CT CT Cross Female 
6850 557 CT CT Cross Female 
6851 558 TT CT Cross Female 
6852 559 CT CT Cross Female 
6926 561 CT CT Continental Female 
6927 562 CT CT Continental Female 
6928 563 CT CC Continental Female 
6929 564 CC CC Continental Female 
6930 565 CC CT Continental Female 
6931 566 CT CC Continental Female 
6932 567 CT TT Continental Female 
6933 568 CT CC Continental Female 
6934 569 CT CC Continental Female 
6935 570 CT CT Continental Female 
6936 571 CT CC Continental Female 
6937 572 CC CC Continental Female 
6938 573 CC CC Continental Female 
6939 574 CT CT Continental Female 
6941 575 CC CT Continental Female 
6131 576 CC CT Continental Female 
6133 577 CT CT Continental Female 
6134 578 CC CT Continental Female 
6135 579 CT CC Continental Female 
6136 580 CC TT Continental Female 
6137 581 CT X Continental Female 
6138 582 CT CT Continental Female 
6139 583 CT TT Continental Female 
6141 584 CC CT Continental Female 
6142 585 CT CT Continental Female 
6143 586 CT TT Continental Female 
6144 587 CT CT Continental Female 
6145 588 CT TT Continental Female 
6146 589 CT CT Continental Female 
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6147 590 CT CT Continental Female 
6148 591 CC CT Continental Female 
6149 592 CT TT Continental Female 
6150 593 CC CC Continental Female 
6461 594 CC CC Continental Female 
6462 595 CT CC Continental Female 
6463 596 CT CC Continental Female 
6464 597 CT CC Continental Female 
6465 598 CT CC Continental Female 
6466 599 CC CC Continental Female 
6467 600 CC CC Continental Female 
6468 601 CT CT Continental Female 
6469 602 CT CT Continental Female 
6470 603 CC CT Continental Female 
6471 604 CT CT Continental Female 
6472 605 CC CT Continental Female 
6473 606 CT X Continental Female 
6474 607 CC CT Continental Female 
6475 608 CT CT Continental Female 
6476 609 CC CC Continental Female 
6477 610 CC CC Continental Female 
6478 611 CT TT Continental Female 
6479 612 CC CC Continental Female 
6480 613 CT CC Continental Female 
6263 614 CC CT Cross Female 
6264 615 CT CT Cross Female 
6265 616 CT CT Cross Female 
6266 617 CT CC Cross Female 
6267 618 CT TT Cross Female 
6268 619 CC CC Cross Female 
6269 620 CC CC Cross Female 
6270 621 CT CT Cross Female 
6271 622 CT CT Cross Female 
6272 623 CC CT Cross Female 
6274 625 TT CC Cross Female 
6260 626 CT CC Cross Female 
6261 627 CT CT Cross Female 
6262 628 CT CT Cross Female 
6251 629 CT CT Cross Female 
6252 630 CC CC Cross Female 
6253 631 TT CT Cross Female 
6254 632 CT CC Cross Female 
6255 633 CC CC Cross Female 
6256 634 CT CC Cross Female 
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6257 635 CT CC Cross Female 
6258 636 CT CC Cross Female 
6259 637 TT CT Cross Female 
9451 638 CT CC British Female 
9452 639 TT CC British Female 
9453 640 TT CC British Female 
9454 641 CT CC British Female 
9455 642 CT CC British Female 
9456 643 CT CT British Female 
9457 644 CT CC British Female 
9458 645 CT CC British Female 
9459 646 CT CC British Female 
9460 647 CT CC British Female 
9461 648 TT CT British Female 
9462 649 CT CC British Female 
9463 650 CT CC British Female 
9464 651 CT CC British Female 
9465 652 TT CC British Female 
9466 653 CT CC British Female 
9467 654 CT CT British Female 
9468 655 CT CC British Female 
9471 658 TT CT British Female 
6521 659 CT CC Continental Female 
6522 660 CT CC Continental Female 
6523 661 CT CT British Female 
6524 662 CC CT Continental Female 
6525 663 CT CT Continental Female 
6526 664 CT CT Continental Female 
6527 665 CC CT British Female 
6528 666 CC CC Continental Female 
6529 667 CT CC British Female 
6530 668 CT CT Continental Female 
6531 669 CT X British Female 
6532 670 CT CC British Female 
6533 671 CT CT British Female 
6534 672 CT CC British Female 
6535 673 CT CT British Female 
6536 674 CC CC British Female 
6537 675 CC CC British Female 
6538 676 CC TT British Female 
6539 677 CC CC Continental Female 
6540 678 CT CT British Female 
6541 679 CT CT Continental Female 
6011 680 TT CC Cross Female 
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6012 681 TT CC Cross Female 
6013 682 CT CC Cross Female 
6015 684 CT CC Cross Female 
6016 685 CT CC Cross Female 
6017 686 TT CC Cross Female 
6019 688 CT CC Cross Female 
6020 689 CT CC Cross Female 
6024 693 TT CC Cross Female 
6025 694 CT CT Cross Female 
6027 696 CT CC Cross Female 
6028 697 TT CC Cross Female 
6029 698 CC CC Cross Female 
6031 700 CT CC Cross Female 
6032 701 CC CC Cross Female 
6033 702 CT CC Cross Female 
6035 704 CT CT Cross Female 
6036 705 CT CC Cross Female 
6221 706 TT CC British Male 
6222 707 CT CC British Male 
6223 708 TT CC British Male 
6224 709 CT CC British Male 
6225 710 TT CC British Male 
6226 711 CT CC British Male 
6227 712 CT CC British Male 
6228 713 TT CC British Male 
6229 714 CT CT British Male 
6230 715 CT CC British Male 
6231 716 TT CC British Male 
6232 717 TT CC British Male 
6233 718 CT CT British Male 
6234 719 TT CC British Male 
6235 720 CT CC British Male 
6236 721 CT CC British Male 
6331 722 CC CC Continental Female 
6334 725 CT CT Continental Female 
6335 726 CC CC Continental Female 
6336 727 CT CT Continental Female 
6337 728 CT CT Continental Female 
6338 729 CT TT Continental Female 
6339 730 CT TT Continental Female 
6341 731 CT CC Continental Female 
6342 732 CC TT Continental Female 
6344 734 CC CT Continental Female 
6345 735 CT TT Continental Female 
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6346 736 CC CT Continental Female 
6347 737 CT CT Continental Female 
6103 738 CT CC Continental Female 
6105 739 CC CT Continental Female 
6106 740 TT CT Continental Female 
6113 741 CC CT Continental Female 
6117 742 CC CT Continental Female 
6161 743 CC CT British Female 
6167 744 CT CC British Female 
6168 745 CC CC British Female 
6169 746 CT CC British Female 
6170 747 CC CT British Female 
6172 748 CC CC British Female 
6174 749 CC CC British Female 
6176 750 CC CC British Female 
6184 751 CC CC British Female 
6186 752 CT CC British Female 
6190 753 CC CC British Female 
6433 754 CT CC British Female 
6437 755 CT CT British Female 
6443 757 TT CT British Female 
6447 758 CT CC British Female 
6564 762 CC CT British Female 
6566 764 CT CT British Female 
6567 765 CT TT British Female 
6569 767 CC CT British Female 
6570 768 CT CC British Female 
6571 769 CT CC British Female 
6572 770 TT CT British Female 
6573 771 TT CT British Female 
6575 773 CC CT British Female 
6348 774 CC TT Continental Male 
6349 775 CT CC Continental Male 
6350 776 CT CT Continental Male 
6352 778 CT TT Continental Male 
6354 780 CT CT Continental Male 
6355 781 CC CC Continental Male 
6356 782 CT CT Continental Male 
6551 783 CT CC British Female 
6552 784 CT CC British Female 
6554 786 CT CC British Female 
6557 789 CT CT British Female 
6558 790 CT CT British Female 
6560 792 CT TT British Female 
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6561 793 CT CC British Female 
6562 794 CC CC British Female 
6563 795 CT CT British Female 
6101 796 CC CC Continental Female 
6102 797 CT CC Continental Female 
6104 798 CT CT Continental Female 
6107 799 CT CC Continental Female 
6108 800 CT CC Continental Female 
6109 801 CT CC Continental Female 
6110 802 CT TT Continental Female 
6111 803 CT X Continental Female 
6112 804 CT TT Continental Female 
6115 805 CT X Continental Female 
6116 806 CT CT Continental Female 
6118 807 CC CT Continental Female 
6119 808 CT CT Continental Female 
6120 809 CT CT Continental Female 
6121 810 CT CC Continental Female 
6162 811 CT CT British Female 
6163 812 CC CC British Female 
6164 813 CT CC British Female 
6165 814 CT CC British Female 
6166 815 CT CC British Female 
6171 816 CT CC British Female 
6173 817 CT CC British Female 
6175 818 TT CC British Female 
6177 819 CC CC British Female 
6178 820 CT CC British Female 
6179 821 CT CC British Female 
6180 822 TT CC British Female 
6181 823 CT CT British Female 
6182 824 CT CC British Female 
6183 825 CC CT British Female 
6185 826 CT CT British Female 
6187 827 CT CC British Female 
6188 828 CC CT British Female 
6189 829 TT CT British Female 
6432 831 TT CT British Female 
6434 832 CT CC British Female 
6435 833 TT CC British Female 
6438 835 TT CT British Female 
6440 836 CT CT British Female 
6441 837 CC CC British Female 
6445 840 CT CC British Female 
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6448 842 TT CC British Female 
6450 844 CT CC British Female 
6455 846 CT CC British Female 
9481 847 CC CC British Female 
9482 848 CT CC British Female 
9485 851 CT CT British Female 
9486 852 CT CC British Female 
9487 853 CC CC British Female 
9489 855 CT CC British Female 
9490 856 CT CC British Female 
9492 858 CC CC British Female 
9494 860 CC CC British Female 
9496 862 CT CC British Female 
9497 863 CT CT British Female 
9499 865 CT CC British Female 
9501 867 CC CT British Female 
9503 869 CT X British Female 
9505 871 CT CC British Female 
9506 872 CC CC British Female 
9508 874 CT CC British Female 
9509 875 CT CC British Female 
9511 877 TT CC British Female 
9513 879 CT CC British Female 
9514 880 CC CC British Female 
9518 884 CT CC British Female 
9520 886 CC CC British Female 
9522 888 CT CC British Female 
9524 890 CT CC British Female 
9526 892 CT CC British Female 
9527 893 CT CC British Female 
9529 895 CT CC British Female 
9530 896 CT CC British Female 
9531 897 CC CC British Female 
9532 898 CT CC British Female 
9533 899 CT CC British Female 
9534 900 CT CC British Female 
9535 901 CT CC British Female 
9538 904 CC CC British Female 
9540 906 CT CC British Female 
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Summary of Genotypes of Animals 
 
 GENOTYPE  CC CT TT  X  Total 
 LEPTIN  150 348 64  None  562 
 POMC  292 189 44  37  562 
 
 
X = DNA samples that failed to amplify on the PCR 
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